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ABSTRACT 
BACKGROUND 
Post surgical adhesion formation is still an unsolved problem and occurs when there is an 
imbalance between fibrin deposition and fibrin clearing capacity in the abdominal cavity. 
Transforming growth factor beta (TGF-β) is associated with fibrosis and hyaluronan has in 
several studies been showed to reduce adhesions. There are limitations to study mechanisms 
in humans, thus experimental models are needed. This work used in vivo and in vitro models 
to study effects of TGF-β and hyaluronan, and may further elucidate their involvement in 
peritoneal repair. 
 
MATERIAL & METHODS 
TGF-β1 and fibrinolytic components were measured in peritoneal tissue in patients (I). In 
models response to increased levels of TGF-β1 on fibrinolytical components in cultured 
mesothelial cells (MC) were investigated (II). Measurements of fibrinolytic components and 
proliferation by hyaluronan were investigated in MC (III & IV). TGF-β isoforms and 
fibrinolytic components were assessed in peritoneal fluid and plasma during surgery, together 
with mesothelial proliferation in vitro (V). 
 
RESULTS 
Increased TGF-β1 levels in adhesion tissue were associated with adhesion formation and 
TGF-β1 correlated to plasminogen activator inhibitor-1 (PAI-1). Increasing levels of TGF-β1 
decreased production of tissue plasminogen activator (t-PA) and increased PAI-1 release into 
the culture media dose dependently in cultured MC. The in vitro studies of hyaluronan on MC 
indicated an increase in fibrinolytic capacity and an increase in proliferation when added. In 
peritoneal fluid during surgery elevated fractions of TGF-β1-2 were found compared to 
plasma. The levels of TGF-β1 in peritoneal fluid correspond to the levels found to increase 
MC proliferation in vitro. 
 
CONCLUSION 
Increased levels of TGF-β1 in peritoneal tissue seem to be associated with adhesions, which in 
part might be explained by local decrease in fibrinolytic response from mesothelial cells. The 
clinical anti-adhesion effect of hyaluronan is unclear, but might partially be explained by 
increased fibrinolytical capacity and increased mesothelial proliferation. Low levels of active 
TGF-β1 might increase mesothelial regeneration in vivo in combination with remained local 
fibrin degradation capacity found in the abdominal cavity during surgery. These findings 
might be of importance in the understanding of peritoneal repair. 
 
 
 
Key words: Adhesion formation, experimental model, cell culture, mesothelial cells, 
peritoneum, fibrinolytic system, transforming growth factor beta, hyaluronan, proliferation 
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INTRODUCTION 
A problem 
The formation of post-surgical adhesions continues to be a clinical problem. One reason for 
adhesions in the peritoneal cavity is prior surgery (1). Early observations indicate that up to 
90% of the patients undergoing abdominal surgery develop adhesion (2). Not all patients with 
adhesions will have clinical symptoms. However, some patients are later admitted to hospital 
with bowel obstruction (2-5). Adhesions can be filmy and easily divided or dense, fibrotic, 
vascularised tissue that requires sharp dissection. Different scoring systems have been used to 
classify adhesions, depending of quality and quantity (6-8). The presence of adhesions may 
cause pain for the patient (9) and contribute to increased costs, surgery time, prolonged 
hospital stay and greater consumption of health care resources (10, 11). 
 
Peritoneal adhesions are an abnormal attachment that forms between tissues and organs 
within the abdominal cavity. However, these abnormal attachments may have had a “positive” 
influence during the evolution of humans. The primary function has likely been to seal any 
leakage, repair and prevent further damage to the individual. Post surgical adhesion formation 
has been described in the literature for more than a hundred years, but is still not completely 
understood (12-14). 
 
This thesis will focus on different experimental models that can be used to explore some of 
the mechanisms that may be involved in post-surgical adhesion formation and to explore the 
influence of surgery and other factors in the development of adhesions. It is noteworthy that 
many of these factors are key components of the normal healing process as well. 
 
The peritoneal cavity 
Peritoneum 
The body cavities are covered with a serous membrane. Besides the pleura and the 
pericardium, the peritoneum is the largest serous membrane with an area of approximately 
2m2 in an adult (15-17). The parietal peritoneum covers the abdominal wall and the visceral 
peritoneum covers the organs within the abdominal cavity. The peritoneum consists of one 
loose connective part containing elastic fibers and a superficial part known as the 
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mesothelium, which consists of a thin layer of mesothelial cells resting on a basal membrane. 
The primary function of the mesothelium has historically been thought to minimize friction 
and to facilitate movement between organs. However, during recent years, the mesothelium 
has emerged as a cellular membrane responsible for many important functions including 
transport through the peritoneum (18) and secretion of extracellular matrix (ECM) proteins, 
growth factors and cytokines (19, 20). In addition, the mesothelium has a function in host 
defence against bacteria, the trafficking of cells and antigen presentation (16, 21) and it’s 
trans-membrane exchange is used in continuous ambulatory peritoneal dialysis (CAPD) (22, 
23). 
 
 
Mesothelial cells 
The basal membrane of the peritoneum is covered by a thin monolayer of mesothelial cells, 
mostly elongated and flat cells that face the abdominal cavity (Figure 1). These cells, 
approximately 25µm in diameter, have the cytoplasm raised over a nucleus that is central 
round or oval (24). They can be divided into squamous-like or cuboidal cells according to 
their ultra structure. The predominantly mesothelial cell is a squamous-like cell. Cuboidal 
cells can be found in the folds of the liver and spleen, at the “milky spots” of the omentum 
and in the area of the diaphragm associated with the lymphatic lacunae (17, 25-27). 
 
The surface of the mesothelial cell is covered by microvilli that vary in length, shape and 
density. They increase the functional peritoneal surface up to 40 m2 (17, 28). Variable 
numbers of microvilli may be seen between different organs, different groups of cells and 
Figure 1: En face Häutchen preparation of
the human peritoneal surface. The mesothelial
surface of the peritoneum was captured on a
pre-frozen glass slide. After removing the
slide from the surface, glass slide was dried
and the mesothelial surface were fixed and
stained in Haematoxyllin/Eosin, Photo with
Nikon E800 Eclipse, P. Falk (2004)
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even between single cells. The surface of a microvilli is covered by glycosaminoglycans with 
the most common being hyaluronan (also known as hyaluronic acid). Hyaluronan has been 
demonstrated both on the cell surface and in pinocytic vesicles. It has been discussed if 
hyaluronan is derived from the systemic circulation. However, hyaluronan seems to be 
produced and secreted locally. Mesothelial cells have a sophisticated system of vesicles and 
vacuoles and like microvilli the concentration of these vesicles and vacuoles varies between 
cells and sites. Vesicles are involved in the transport of fluid and particulate matter from the 
peritoneal cavity through the peritoneal surface. Experimental studies indicate that particles 
up to 100 nm can be transported through the mesothelial cell via micropinocytosis. The 
interstitial area between the mesothelial cells is complex with adjacent cells often overlapping 
and widely spread junctions and desmosomes between cells. In response to an activated 
immune system is likely that an inflammatory response on the mesothelial surface results in 
the release of cytokines. This action polarizes the mesothelial surface and promotes trans-
mesothelial migration of white blood cells, including neutrophils and monocytes (17, 24, 26, 
27, 29-33). 
 
 
Furthermore, under normal or stimulated conditions, mesothelial cells have the capacity to 
produce several factors such as inflammatory proteins and ECM molecules involved in 
inflammation and tissue repair. In certain conditions, this process is regulated by growth 
factors, such as transforming growth factor-beta (TGF-β) (34). In experimental settings 
mesothelial cells are capable of producing interleukin-15 which is important in the process of 
antigen presentation to mononuclear cells (21). Mesothelial cells are also important in 
maintaining and balancing the fibrinolytic clearing capacity, which affects formation of 
Figure 2: Mesothelial cells are
under normal or stimulating
conditions able to produce one or
more of the following factors as
reviewed by S. Mutsaers 2002.
Cultured mesothelial cells, Photo
by P. Falk (2003)
•Cytokines/Chemokines
•IL-1, -6, -8, -15, MCP-1, RANTES, etc
•Growth factors
•TGF-β, PDGF, FGF, VEGF, etc
•ECM-related molecules
•Collagen I, III, Fibronectin, Hyaluronan, etc
•Proteases
•MMPs, TIMPs, etc.
•Coagulation/Fibrinolysis
•PA , PAI, Thrombin, etc.
•Adhesion molecules
•ICAM, VCAM, etc.
•Other molecules
•HSP, NO, etc.
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adhesions, by the production and secretion of plasminogen activators and their inhibitors (24, 
35, 36). Mesothelial cells have the capacity to produce a variety of factors and some of them 
are summarized in Figure 2 (24). 
Peritoneal repair and regeneration 
The exact mechanism behind peritoneal and mesothelial repair is not fully understood. In 
1919 Hertzler found that small and large peritoneal defects healed at the same rate (37). It was 
concluded that there must be other healing processes in place in addition to proliferation and 
migration from the wound edges (as in dermal wound healing). Under normal conditions 
regenerative properties of the peritoneum are remarkable, with rapid simultaneous 
epithelialization of the entire surface in a short period of time. 
 
 
Trauma stimulates structural cell changes to facilitating repair. After trauma to the peritoneum 
in the form of a lesion, the damaged area is invaded and infiltrated by inflammatory cells 
within the next 36 hours. Due to increased vascular permeability, caused by histamine, an 
inflammatory response results in the release of active components. Polymorphonuclear 
(PMN) cells, macrophages and platelets together with fibrinogen in the peritoneal exudation 
forms a primary fibrin clot. Under normal conditions fibrinolytic activity will degrade the 
fibrin resulting in the formation of fibrin degradation products (FDP) (16). A number 
processes have been proposed which result in recruitment of new mesothelial cells, including 
migration of nearby cells, exfoliation of cells from adjacent or opposing surfaces, free floating 
cells, transformation of serosal macrophages or underlying fibroblasts, submesothelial 
mesenchymal cells or bone marrow derived precursors (24) (Figure 3). During ideal 
conditions both small and large defects on the peritoneum will regenerate within a week after 
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the damage (16, 38) (Figure 3). Although regeneration can lead to restoration of the peritoneal 
lining this is not always the case after surgery. Damaged surfaces can adhere to each other 
and form a postoperative adhesion, which in turn can cause complications. 
Adhesion formation 
The formation of postoperative peritoneal adhesions is specific to the serosal response to 
injury. Post surgical adhesions typically occur when there is an imbalance between deposition 
and degradation of fibrin resulting in persistent remnants of the fibrin matrix. Histological 
studies have shown that the healing process is similar to normal healing at the first, but a few 
days post surgery the fibrin matrix is then gradually invaded by reparative cells and the fibrin 
is replaced by connective tissue containing macrophages and fibroblasts. The adhesions are 
often covered with mesothelial cells and are also containing blood vessels. After one week 
fibroblasts produce collagen bundles and elastin (39). Nerve fibers have also been detected in 
abdominal adhesion (38, 40). 
 
 
The fibrinolytic system has a major impact in the early phase of postoperative adhesion 
formation. Under certain conditions, an imbalance of one or more components in this system, 
normally involved in the healing of the peritoneal surface, may leave an excess of fibrin 
matrix in the wound area thus contributing to adhesion formation (Figure 4). 
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The fibrinolytic system 
In many biological systems, it is critical to maintain equilibrium between stimulators and 
inhibitors. The degradation of fibrin is highly regulated by the fibrinolytic system. 
Briefly, at the end of the coagulation cascade fibrinogen is converted into fibrin in the 
presence of thrombin. Fibrin together with aggregated platelets form the primary clot that 
stops the initial bleeding. When this function is complete the clot needs to be lysed to restore 
vascular patency. The fibrinolytic system is capable of lysing the primary clot by converting 
plasminogen into plasmin. This conversion is balanced by plasminogen activators and their 
inhibitors. Complete resolution of the fibrin clot results in fibrin degradation products (FDP) 
(41). Plasmin has the ability to resolve fibrin completely. However, extended fibrin 
generation with limited or no degradation results in a permanent structure by conversion of 
fibrin mesh into connective tissue. 
 
The fibrin clearing capacity in the peritoneal cavity is similar to that of the systemic 
circulation. Similar to the endothelium, cells covering the peritoneal surface are capable of 
producing and secreting tissue-type plasminogen activator (t-PA) and urokinase plasminogen 
activator (uPA) and the plasminogen activator inhibitor -1 and -2 (PAI-1, PAI-2) (35). A 
balance between plasminogen activators and their inhibitors is crucial for the peritoneal fibrin 
clearing capacity (42, 43) (Figure 5). 
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Plasminogen activators 
Plasmin and plasminogen activators are members of a glycoprotein family (serine proteases) 
and are present as active forms or as complex bound to one of their inhibitors. 
 
t-PA is the main plasminogen activator in plasma and has been identified in many types of 
human tissue (35, 44, 45). It is highly fibrin specific and t-PA activity may be increased up to 
1000-fold in the presence of fibrin (46). Active t-PA will be rapidly inactivated by 1:1 
complex binding to the inhibitor PAI-1 (47, 48). The main source for t-PA production is 
believed to be the vascular endothelium. However, there is evidence that other cells like 
macrophages (49) and mesothelial cells (35, 36) also have the capacity to produce and secrete 
t-PA. Hence, in the peritoneal cavity, the mesothelium is likely to be a major source of t-PA. 
 
uPA is another plasminogen activator, present in plasma and tissue and is the main activator 
in urine (50, 51). It is likely that uPA and t-PA are equally efficient in terms of fibrin 
degradation capacity (52). There is evidence that uPA can be present in the abdominal cavity 
(53) released from mesothelial cells (36) and it may be of importance in peritoneal wound 
healing. It is also reported that uPA plays a role in inflammation and spreading of metastatic 
cancer (54, 55) by facilitating the migration of cancer cells into other tissues. The role of uPA 
and its receptor in ovarian cancer (56), as well as surface bound plasminogen activation in 
tumour growth (57) has also been documented. However, since t-PA is highly fibrin specific 
(46, 58) and more than 95% of the fibrinolytical capacity in the peritoneal cavity is exerted by 
t-PA (59, 60), the role of uPA in the peritoneal tissue repair is poorly understood. 
 
Plasminogen activator inhibitors 
PAI-1 is the primary inhibitor of both t-PA and uPA and is produced and secreted by 
endothelial cells in the vascular wall (61-63). Moreover, PAI-1 has also been shown to be 
produced or secreted by platelets (64), macrophages (65), fibroblasts (66), and by mesothelial 
cells (35, 36, 67). Several stimuli including, inflammatory mediators or endotoxin (36), may 
also promote secretion of PAI-1 in cell culture systems. PAI-1 can inactivate t-PA in plasma 
within a few minutes (63). During inactivation PAI-1 forms inactive complexes with both t-
PA and uPA. 
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PAI-2 was first found in placenta (68) and was known as “the placenta inhibitor”, for a long 
period of time. In pregnant women plasma concentrations of PAI-2 increased during 
pregnancy, with a peak and an immediate decrease associated with the delivery (69).  Later it 
was demonstrated that PAI-2 was present in amniotic fluid (70), in plasma during sepsis (71), 
and in the peritoneal cavity and secreted by macrophages (72) and mesothelial cells (36). A 
role of PAI-2 in ovarian cancer has also been described (73). PAI-1 is more fast acting than 
the PAI-2 and it has been suggested that PAI-1 and PAI-2 have different biological functions 
(74). Although PAI-2 has been detected in the peritoneal environment (74) its role in 
peritoneal tissue repair is unclear. Like PAI-1, PAI-2 also forms inactive complexes with the 
plasminogen activators t-PA and uPA. 
 
Other active plasmin inhibitors in blood are α2-macroglobulin, α2-antiplasmin and α1-
antitrypsin. Of these, α-2 antiplasmin is the most specific to plasmin. Since these inhibitors 
act more slowly than plasminogen activator inhibitors, it is conceivable that they could have 
different biological functions, and the role of plasmin inhibitors is poorly understood in the 
context of peritoneal fibrinolysis (63, 75). 
 
Factors in the peritoneal environment 
There are additional components in the peritoneal environment that can affect peritoneal 
tissue repair directly, or indirectly, via the fibrinolytic system. This would include factors that 
are likely to be produced or secreted into the abdominal cavity. 
 
Transforming growth factor beta 
TGF-βs are multifunctional cytokines and have unique abilities to initiate activities resulting 
in net synthesis of new connective tissue. TGF-βs can interact with interleukins and other 
cytokines in the activation of the immune system. They also have the capacity to stop the 
proliferation of cells, and initiate differentiation in a variety of cell systems such as 
endothelial cells, keratinocytes and some malignant cells (76). 
 
TGF-β belongs to a superfamily of polypeptide molecules, and are designated TGF-β1-5. 
There are three mammalian forms of TGF-βs (TGF-β1-3). TGF-β4 is found in chickens, and 
TGF-β5 is found in frogs (77, 78). TGF-β1-3 are secreted in a latent form from cells including 
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platelets (79) as a precursor. This latent form can be converted and activated in several ways, 
including proteolytic cleavage by denaturing agents such as urea or guanidine hydrochloride 
(79), extreme pH and temperature changes. These mechanisms have been demonstrated in 
vitro (80, 81) and similar mechanisms are likely to be of importance in vivo (82). In cell 
proliferation, the effect of TGF-β is determined by its influence on the cell cycle and the 
effects on growth arrest, proliferation and apoptosis. In most epithelial, endothelial and 
hematopoetic cells, TGF-β inhibits cell proliferation by blocking the cell in G1 phase (83). 
However, the effect of TGF-β on the peritoneal mesothelial lining is not fully elucidated. 
 
TGF-β also interacts with the ECM, which is important in the wound healing processes. TGF-
β normally stimulates ECM production by mesenchymal and epithelial cells, at the 
transcriptional level (84). The stimulatory role of TGF-β in scar formation, is well 
documented (85). TGF-β can promote ECM production by increasing synthesis of matrix 
proteins, including collagen type I, II, III, IV, V, VII and fibronectin (86, 87) together with an 
inhibiting of ECM proteolysis and degradation. These mechanisms combined leads to a net 
accumulation of ECM. This is accomplished by the inhibitory effect of TGF-β on the 
secretion of matrix degrading enzymes such as matrix metalloproteinases (MMPs), 
specifically MMP-1 and -3 and the effect on plasminogen activators (88). Additionally, the 
expression of inhibitors of proteolytic enzymes is increased by TGF-β such as PAI-1 and 
tissue inhibitor of matrix metalloproteinases-1 and 2 (TIMP-1, -2) (89). Not surprisingly, 
TGF-β1 plays a central role in wound healing and in scar formation by stimulating fibrosis 
(87, 90, 91). Antibodies against TGF-β1 have been shown to reduce the scarring process (92) 
in subcutaneous wounds in animals. 
The effect of TGF-β on key mechanisms in peritoneal tissue repair has only been partially 
evaluated. TGF-β1 has been reported to downregulate mRNA expression of t-PA (93) and 
increase the mRNA expression of PAI-1 in human bronchial epithelial cells (94) and in 
transformed mesothelial cells (95). In human pleural cells, TGF-β1 has been observed to affect 
fibrinolytic components (20). However, it is unclear if these effects are similar in human 
peritoneal mesothelial cells. In experimental models of adhesion formation it has been 
demonstrated that the addition of TGF-β1 can increase the numbers and severity of intra 
abdominal adhesions after surgery (96). Moreover, by using a neutralizing antibody to TGF-
β1, adhesions could be reduced (97) in animals supporting a role of TGF-β in peritoneal 
repair. 
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There might be multiple sources for TGF-β in the abdominal cavity; degranulation of platelets 
at sites of tissue injury, from surrounding tissue and from the mesothelium itself. It is 
reasonable to assume that if TGF-β is present in the abdominal cavity this would affect the 
fibrin degradation capacity locally, in favor of the formation of adhesions.  
 
Hyaluronan 
To be consistent, this work refers to hyaluronic acid, hyaluronan or sodium hyaluronate as 
hyaluronan.  
The microvilli on the mesothelial cells are covered by glycosaminoglycans. The most 
common is hyaluronan (24, 30), a high molecular weight polysaccharide first described and 
found in the vitreous fluid (hyalos) in the eye. Hyaluronic acid, later introduced as hyaluronan 
(98), has important biological functions (99) in tissues. The concentration of hyaluronan is 
high in tissues undergoing healing processes (100, 101). Hyaluronan has also been reported to 
affect inflammatory response (102, 103). There is a relationship between hyaluronan and 
mitosis, as well as the detachment and movements of cells (104-106). It has also been 
described that an environment rich in hyaluronan provides a hydrated matrix that facilitates 
cell migration (107). 
 
Hyaluronan, or hyaluronan based agents to reduce the formation of post-surgical adhesions 
have been used both in experimental animal models (108-111) and in clinical settings (112-
117). Carboxymethylcellulose and hyaluronan (HA-CMC) is one of the most studied 
materials in this context. In patients undergoing colectomy the use of a of HA-CMC 
membrane (114) was effective in reducing adhesion formation. Moreover, in gynaecological 
patients undergoing laparotomy use of a hyaluronan solution as a precoating solution, was 
reported to be effective in reducing the formation of adhesions (115). The clinical outcome as 
reviewed by Reijnen et al (118) was that the incidence of severe adhesions was reduced by 
approximately 40 per cent. 
 
There are several mechanisms that might explain why hyaluronan-based agents can reduce 
adhesion formations. The mechanical separation of the peritoneal surfaces during the first 
post-operative days may be the most important mechanism. General improvement of the 
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healing process due to the present hydrated matrix might also be of importance. However, 
there might be local effects on the mesothelial lining, but this is poorly understood. 
 
Other factors in the peritoneal environment 
Besides TGF-β and hyaluronan other factors are present in the peritoneal cavity. They could 
also influence the repair processess. Both matrix metalloproteinases (MMPs) and their 
inhibitors (TIMPs) have been demonstrated in the peritoneal environment and are likely 
involved in peritoneal tissue repair. Both of these are affected by TGF-β resulting in a net 
accumulation of connective tissue. Since the function of MMPs is to completely or partially 
degrade the extra cellular matrix, an imbalance of MMPs may influence in the healing process 
as well (14, 81, 87, 89). 
Cytokines are found in the peritoneal environment and several mediators may be of 
importance in the inflammatory response. Both tumour necrosis factor-alpha (TNF-α) and 
lipopolysaccharide (LPS) are likely to be involved in normal peritoneal healing and during 
peritonitis. Interestingly, these factors have been reported to affect the fibrin clearing capacity 
in the peritoneal cavity (35, 36). Other factors such as interleukins and adhesion molecules are 
also most likely involved in the peritoneal healing process as reviewed (14, 119). 
 
In the present study, the focus has been on two factors; TGF-β and hyaluronan. 
 
The use of experimental models 
There are several important reasons for using experimental models in the study of peritoneal 
tissue repair. Firstly, the identification and isolation of mechanisms influencing various 
biological functions could be performed and monitored in a controlled environment. 
Secondly, the use of controlled experimental settings allows the study of these effects over 
time, which would be difficult to perform in a clinical setting. Thirdly, in the clinical setting 
the peritoneal cavity is available for only a short period of time during surgery, which could 
influence interpretation of results. Finally, experimental models are important in the 
understanding of biological effects likely to occur during abdominal surgery since 
experimentation on clinical subjects poses limitations. 
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AIM OF THE THESIS 
The aim of this thesis was to investigate the effects of transforming growth factor beta and 
hyaluronan using different experimental models in order to further understand mechanisms of 
peritoneal repair. 
 
The specific aims were: 
 
- To investigate the presence of transforming growth factor-beta 1 (TGF-β1) in 
peritoneal tissue in patients with adhesion formation and its possible relationship with 
fibrinolytic components (Paper I) 
 
- To determine whether TGF-β1 influences the expression of fibrinolytic components in 
cultured human peritoneal mesothelial cells (Paper II) 
 
- To determine whether hyaluronan affects the expression of fibrinolytic components in 
cultured human peritoneal mesothelial cells (Paper III) 
 
- To determine whether hyaluronan affects proliferation rate in cultured human 
peritoneal mesothelial cells (Paper IV) 
 
- To a) investigate the presence and activation profile of TGF-β1, TGF-β2 and TGF-β3 
in the human peritoneal cavity and to compare with that of plasma during surgery in 
the clinic; b) investigate the effect of different TGF-β isoforms and concentrations on 
the mesothelial proliferation rate in experimental models (Paper V) 
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METHODOLOGICAL CONSIDERATIONS 
General considerations 
Sampling of human material and isolation of human peritoneal mesothelial cells was 
approved by the Regional Ethics committee at Göteborg University, Göteborg, Sweden.  
All subjects consented prior to participation. 
 
The initial human study (Paper I) 
Question 
The question in the first study was whether transforming growth factor-beta 1 (TGF-β1) is 
present in the peritoneal tissue in patients, and if so investigate the possible relationship of 
TGF-β1 with fibrinolytical components. 
 
Human subjects 
In the first study, the role of TGF-β1 in human peritoneal tissue and its possible relationship 
with decreased fibrinolytic capacity was investigated. For this reason, peritoneal biopsies 
were taken from twenty-two patients undergoing abdominal surgery for a colorectal disease. 
All patients (12 men and 10 women) had previously undergone surgery and all had pre-
existing adhesions to varying degrees at the operation. Patients were excluded if any intra-
abdominal infections or disseminated cancer was present. The mean age of subjects was 68 
(range 37-91) years at the time of surgery. 
 
Tissue sampling 
A 5x5 mm biopsy was excised from the parietal peritoneum by dissecting the peritoneum 
from the underlying tissue. Furthermore, from some patients it was possible to sample 
adhesion tissue during adhesiolysis. During sampling, care was taken not to include 
extraneous tissue to minimize confounding factors. For this reason it was only possible to 
sample adhesion tissue from 10 out of 22 patients. Since blood include the factors of interest 
all tissue samples were quickly rinsed in saline solution to remove blood. Thereafter samples 
were put in pre-labelled air tight tubes and frozen at -70°C. Biopsies were stored frozen until 
processed further with homogenisation and biochemical assays. 
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Tissue homogenisation and protein extraction 
Both peritoneal and adhesion samples were homogenised in the same manner. The method 
was developed to assay protein concentration in tissue and has been previously described in 
detail (43). All tissue samples were homogenised in batches to minimise effects of systematic 
multiple processing errors in tissue handling. Briefly, both peritoneal and adhesion tissue 
samples were rinsed in ice cold (0°C) homogenisation buffer (PBS pH 7.4, sodium chloride 
0.5 mol/L, Triton X-100, 0.01%), weighed, cut into smaller pieces and transferred to an ice-
cold tube to a final concentration of 40 mg tissue/mL buffer. Homogenisation was performed 
using an Ultra Turrax homogenizer which was gradually increased in speed to 24 000 rpm. 
The homogenate was aspirated on 0°C ice into an Eppendorf tube for centrifugation at 10 
000g for 3 min at 4°C. The supernatant was aliquoted in several small 250µL tubes and stored 
in -70°C until biochemical assay. 
 
Several types of extraction buffers have been used for the extraction of proteins from tissues. 
Depending on the factor assay, a range of buffers can be used for a particular assay. The 
buffer used in the present work was selected because of its lack of interference with 
subsequent assays. This buffer has been used to process tissue from peritoneum and adhesion 
tissue (120-122), colon (123), appendix (124), and certain tumours (125-127) with 
reproducible results. The homogenisation technique have been reported to be used to extract 
proteins including snap-freezing of tissue followed by crushing, detergent lysis, or controlled 
mechanical homogenisation by using an electric homogenizer (128, 129). The current method 
using an electric homogenizer is convenient since it is useful for both protein extraction and 
RNA extraction. Moreover, the homogeniser can easily be cleaned, and even autoclaved if 
needed, minimizing systemic errors. 
 
Efficiency of extraction 
A potential confounding factor could be the effectiveness of protein extraction. In the present 
experimental studies on repeated extractions on the same tissue sample, it was observed that 
almost all of the protein fraction (>97%) was extracted from the tissue during the first 
process. Thus, the technique was efficient and results obtained likely to accurately reflect 
tissue concentrations. 
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However, a disadvantage of the method is that the homogenizer has a limited homogenate 
volume of approximately 1-3 mL. We have previously observed that an optimal 
weight/volume ratio is about 40 mg tissue per mL buffer (130). Because of this, the maximum 
amount of tissue that can be in each sample is approximately 120 mg, which provides 
sufficient homogenate volume for several assays. On the other hand, we have also discovered 
that the minimal tissue weight is 10 mg by doing serial dilutions of the same sample. These 
experiments showed that samples less than 10 mg increased the error substantially 
(unpublished observation). Samples less than 10 mg have therefore been avoided, and none of 
the biopsies used in the study were below 40 mg each. 
 
Biochemical assays 
In the initial study, the detection of proteins was performed using commercial available 
enzyme-linked immunosorbent assay (ELISA). By using an antibody-antigen reaction, as well 
as an enzyme reaction, this technique usually converts a peroxidase sensitive substrate into a 
colour. Light absorption at a certain wavelength is then quantified using a spectrophotometer 
to assess the concentration. Internal standards of known concentrations are used to quantify 
the optical densities of the test samples. The antibody-antigen reaction in the initial step 
makes these assays very specific to the target. However, depending on what epitope the 
antibody is directed to, the assays cannot always discriminate different conformations of a 
protein such as a latent or active form. 
 
In the first study, levels of t-PA antigen, uPA antigen and PAI-1 antigen were assayed with 
commercial assay kits from Biopool (Umeå, Sweden). The inactive complex between t-PA 
and PAI-1 (t-PA/PAI-complex) was measured using an assay from Novo Nordisk (Bagsvaerd, 
Denmark). 
A method from Promega was used to measure both the active and total amount of TGF-β1. 
First, the active form was assayed. Then the latent TGF-β1 form was assayed following 
activation by acidification of an additional sample with HCl (1 mol/L) to pH 2.7-3.0 in a 
separate tube followed by neutralising and further dilution. The total amount can then be 
analysed on a separate immuno plate in an additional assay as described by the manufacturer.  
In all assays the detected protein was normalised to the wet weight of the homogenised tissue. 
This method was well established in the laboratory and has been observed to be comparable 
to normalizing to total protein content or to DNA (120). 
  24  
 
Variability of the assays and quality control 
Intra-assay variations reflect the variations between several samples within the same ELISA 
plate and inter-assay variations, the variations between several plates. These variations are 
known as the coefficient of variation (CV) and are expressed in % as the product of the 
standard deviation divided with the mean. For the assays in the present study the inter-assay 
variations for t-PA and uPA antigen was 10% and for PAI-1 9% according to the 
manufacturer. The inter-assay variation for the t-PA/PAI-1 complex was 10%, and the intra-
assay CV was below 9% for all fibrinolytical factors. For TGF-β1 the inter-assay variation 
between several immuno plates was 1.6% and the within assay variation was 11.6% according 
to the manufacturers specification when 20 determinations were performed with 4 different 
operators. The intra-assay variation for the TGF-β1 assay is comparatively high. However, this 
assay was evaluated in the lab before, during and after this study and a value between 5 and 
10 % was more likely to be applicable when 3 operators were involved. 
The number of operators was kept to a minimum to standardize these procedures and to 
minimize intra-operator variability. All tissue homogenisations and protein extractions were 
done by a single operator, and the ELISA assays were performed by two persons. Quality 
control of these assays included samples with known concentrations (usually seven different 
concentrations) and a reagent blank on each plate. Additionally, each plate had several control 
samples (both at high and low concentrations) that were used in between several ELISA 
plates to assess the inter assay variability. Unexpected values or values that differed more 
than 10% between the replicates were reanalysed. A comprehensive quality tracking system 
was established from start of assay to the final dataset. Finally, a standard operating procedure 
for each assay was established. These procedures were used for all assays performed at the 
laboratory, including this thesis (Paper I to V). 
 
Scoring of adhesions 
It is well known that adhesion formation is variable and that the quality of adhesions can be 
different. In order to categorize pre-existing adhesions, a scoring system which has been used 
during pelvic surgery (8) was adapted for scoring abdominal adhesions. Because of the 
inherent challenges in categorizing adhesion formation, the system was simplified to describe 
objective findings rather than to utilize quality assessments. For example, extent of adhesions 
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was categorized into either the site of previous surgery (to the site) or to well beyond the 
surgical site (extensive). The quality of adhesion was simplified into two groups reflecting the 
potential clinical impact as filmy (separated by blunt dissection) or vascular (separated by 
sharp dissection and causing bleeding). Lastly, an assessment was made whether an adhesion 
distorted tissue planes to the extent there was a risk of organ damage during adhesiolysis 
(120). All assessments were made by experienced surgeons. 
 
 
The first mesothelial study (Paper II) 
Question 
In the second paper, the question was whether different concentrations of TGF-β1 influenced 
the expression of fibrinolytic components in cultured human peritoneal mesothelial cells by 
measuring the effect at the protein and mRNA level. 
 
Cell culture 
A cell culture model using mesothelial cells had been established. Cell culture and other 
experimental models to study local mechanisms in vivo have been developed and utilized for 
a number of years in the lab with both endothelial cells derived from human umbilical cords 
(HUVEC) and from adult veins (HAVEC) (131-134) and from cultured fibroblasts derived 
from human abdominal skin tissue (135). Culture conditions and techniques for identification 
are similar between endothelial cells and mesothelial cells. The methodological principles for 
isolation and general culture of mesothelial cells will be described further. 
 
Mesothelial cell culture 
The first mesothelial cell culture model established in the laboratory was based on the work 
done by van Hinsbergh et al (35). However, the Dutch group used omentally derived 
mesothelial cells and the present work uses cells derived from another source. Different 
techniques for isolating mesothelial cells and the identification of cultured mesothelial cells 
have been described in detail (36). The mesothelial cells used in the present study were 
isolated from a total of four patients undergoing elective surgery for colorectal reasons. None 
of the patients had any ongoing infections or peritonitis. 
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The cells were isolated as previously described (36). In brief, aspirated peritoneal fluid was 
put in a 50 mL tube and centrifugated at 650g in 20°C for 10 min. The supernatant was 
discarded and the pellet suspended in 5 mL complete E199 culture medium. This medium 
contained; Medium E199, Foetal Calf Serum (FCS), L-glutamine, antibiotics (PEST), ECGF 
prepared according to Maciag et al (136) and Heparin. The cells were then put into a 25cm2 
culture bottle (Cell+, Sarstedt, Germany) and incubated (Forma, Thermo Fisher) at 37°C with 
a 5% concentration of CO2 to maintain pH of the culture medium at pH 7.3-7.4. 
The suspension of cells was left to attach to the bottle and rinsed with fresh culture medium 
the next day. All cultures were monitored using an inverted microscope (Axiovert 25, Carl 
Zeiss AG). Complete culture medium was changed every second or third day. The cultures 
were further sub-cultivated with trypsin/EDTA solution when a 75-85% confluence was 
reached. A split ratio of 1:2-1:4 was used depending on the size of the seeding area and the 
experimental setup. 
 
 
Identification of mesothelial cells 
Identification of mesothelial cells was performed using an immunofluoroscence technique 
based on previously described methods (35, 36, 137, 138). Briefly, established parallel 
cultures were assessed visually by inverted microscopy for their morphologic appearance. 
Mesothelial specificity was assessed using primary antibodies against intra cellular 
cytokeratin -8, -18, -19, vimentin, von Willebrand factor and fibroblast specific antibodies, 
together with FITC-labelled secondary antibodies and an UV-light source on the microscope. 
Morphological elongated appearance (Figure 6) and positive immunostaining for cytokeratin 
and vimentin in cells, which were negative for endothelial and fibroblast antigen indicated 
  27  
mesothelial cell cultures. Using this methodology it was confirmed by electron microscopy 
that these cells had microvilli and thus matched the characteristics of mesothelium (36). 
As previously mentioned, primary cultured mesothelial cells lose their specific mesothelial 
phenotype after the fourth passage in culture (36) and a regression towards a more fibroblast 
like cell was seen when cells were cultured beyond the fourth passage. For that reason, no 
experiments using cells were performed after the third passage. 
 
Sources of mesothelial cells 
It has been reported that by homogenizing biopsies from human omental tissue, cells could be 
isolated during extraction and subsequent centrifugations (35). Since the omentum is rich in 
capillaries, potential contamination with endothelial cells, is a possibility. Thus, it is 
imperative to rule out contamination with endothelial cells. In the present thesis cells 
originated from the peritoneal fluid. When different mesothelial isolation techniques were 
compared the use of peritoneal fluid seemed preferable since it was a repeatable and less 
invasive method than extracting a piece of tissue from the omentum and at the same time 
minimized risk of contamination from endothelial cells. 
Another potential source could be a transformed cell line. During initial experimental set-up 
the transformed cell line, Met-5A, was used to establish growth time, correct split ratio, etc. 
before the main experiments were performed. However, it was soon discovered that this 
particular cell line did not express fibrinolytic components to the same extent as human 
primary isolated cells (unpublished observation) when assessed after stimulation with 
proinflammatory agents (TNF-alpha) or endotoxin (LPS) (35, 36). Thus, the use of a 
commercial available transformed mesothelial cell line for these investigations did therefore 
not seem to be an attractive option.  
To enable a steady supply of cells for multiple experiments cryopreservation was used. 
Parallel cultures from some of the isolated cell lines were stored in cryo tubes submerged in 
liquid nitrogen for use in confirmatory or complementary tests. The liquid nitrogen storage 
did not affect culture conditions or immunological specificities when compared to the results 
from the original cultures (unpublished observation). 
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Biochemical assays 
As with the initial study, all of the assays used were commercial assays; t-PA antigen was 
assayed using Imulyse t-PA, PAI-1 and PAI-2 antigen was assyed using TintElize PAI-1 and 
TintElize PAI-2 (Biopool, Sweden) and urokinase antigen levels were detected by EUMIX-5 
(Monozyme, Denmark). The active fraction of t-PA and the complex between t-PA and PAI-1 
were detected using Funktionell tPA and Funktionell tPA/PAI-1 complex (NovoNordisk, 
Denmark), respectively.  
 
In contrast to the ELISAs used the active fraction of t-PA is measured by using an antibody to 
bind the t-PA molecule to the bottom of the assay plate, without blocking the active site of the 
protein. As previously described, the in vivo function of t-PA is to convert the present inactive 
plasminogen into active plasmin, a reaction that is enhanced by the presence of fibrin. In the 
“Funktionell t-PA” assay, plasminogen and fibrin dimer is added to initiate the reaction. In 
conjunction with a plasmin sensitive substrate the reaction results in a measurable color. 
In the present paper, biochemical assays were normalized to cell count and expressed as 
concentration/106 cells to reduce errors due to difference in cell density. 
 
TGF-β1 treatment and experimental settings 
The concentrations selected for TGF-β1 stimulation were from the same as previously 
reported under similar conditions (93, 95). TGF-β1 used for this study was purchased 
commercially (R&D Systems) and diluted to 0.1, 1 and 10 ng/mL according to instructions 
from the manufacturer. 
Human mesothelial cells from the second passage were seeded into 3.83 cm2 12 well dishes. 
Freshly trypsinated cells were suspended into fresh culture medium at a cell density of 
0.9x105 cells/well. Cells were further cultured until confluent. In order to synchronize the cell 
cycles of the cultured cells, an additional 48 hours exposure to reduced serum concentration 
of FCS (10%) was used. Following this, the conditioned media were removed and replaced 
with medium containing the different TGF-β1 concentrations (0.1-10 ng/mL) and with a 
further reduction in FCS (0.2%) to minimize impact of potential TGF-β1 contamination from 
FCS. Cells with no addition of TGF-β1 but medium only served as untreated controls. After 
24 hours, conditioned medium were collected and frozen in aliquots for protein detection. 
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RNA preparation 
In order to protect samples from RNA degradation, all chemicals and materials used for cell 
culture and molecular biology were purchased RN:ase free and handled aseptically. Total 
cellular RNA was isolated using Trizol (Life Technologies) followed by centrifugation with 
chloroform and isopropyl alcohol. The aqueous phase, containing the total RNA, was then 
washed with alcohol and dried. The RNA pellet was dissolved in water and a small sample 
was diluted and measured as optical density at wavelength 260 and 280nm (A260/280nm ratio) in 
order to examine RNA/DNA purity. RNA degrades easily and the A260/280nm ratio of degraded 
RNA has a ratio that is often less than 1.6. Ideally, this ratio should be between 1.6-2.0, as 
described by the manufacturer. In the present study, the ratio of the first experimental set-up 
measured between 1.4-1.6. However, in the later experiments the preparations generated 
ratios above 1.7. Total RNA with a ratio above 1.7 was used for additional experiments. 
 
Detecting the mRNA levels 
The technique for detecting mRNA for the fibrinolytical targets used in the present work was 
established at the Institute for Wound Research, University of Florida (Gainesville, FL, USA). 
Individual training on laboratory techniques was done on three separate occasions and 
methods were subsequently implemented in the laboratory in Göteborg. This paper was the 
first one from our group describing the development of the quantitative competitive reverse 
transcription polymerase chain reaction (Q-RT-PCR) technique (Paper II). 
For detection of fibrinolytic mRNA by this technique, an external synthetic multiprimer 
cDNA standard was used generously provided by Prof. Chegini at the Institute for Wound 
Research. The technique using an external cRNA template has been described previously 
(139, 140). A more detailed description of the cDNA standard is given in Paper II. The 
procedure is based on the insertion of sequences of t-PA, uPA, PAI-1, PAI-2, uPA receptor 
and G3PDH into a plasmid. 
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In order to obtain a sufficient amount of total RNA, several cell culture wells were pooled 
together in two groups of three each. The total RNA was isolated from the wells (Figure 7) 
and 2 µg of total cellular RNA subjected to a standard reverse transcriptase reaction to 
develop a cDNA library. In separate small PCR-tubes, equal amounts of unknown cDNA 
sample were added together with one of several dilutions of external cRNA standard (103-108 
template copy numbers). All tubes were then subjected to a standard PCR reaction with 1.5 
minutes at 94°C, 2 minutes at 58°C and 3 minutes at 72°C for a total of 40 cycles as 
previously described (140). The resulting PCR products were loaded together with a 100 bp 
(base pair) molecular marker in a submarine gel electrophoresis on a 1.8% agarose gel 
containing ethidium bromide 0.1% and then connected to a voltage source at 120 volts DC for 
30-40 minutes. Target and sample products from the PCR reaction were separated according 
to their base pair sizes (Table 1). All gels were then illuminated with UV-light, photographed, 
scanned in a flat-bed scanner and finally saved as tiff-files on a personal computer. 
Using an image software program (NIH Image v1.54) different band intensities were 
determined and normalised to the different base pair sizes. For each reaction, the intensities of 
band ratios, between the unknown samples and the known template, within each lane (for 
each PCR tube), were plotted (Y-axis) on a log-log standard curve against the template copy 
number (X-axis). When the ratio between the sample and the internal standard is equal 
(ratio=1) on the Y-axis, the concentration could be read on the X-axis expressed as 
concentration of mRNA copies, as previously described (Figure 7) (140). The presence of the 
house-keeping-gene G3PDH was used as a positive control in all cDNA samples.  
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This technique was one of the first methods for quantification of a PCR result against a 
known amount from an external standard template. There are several ways for semi-
quantitative detection, where the target gene is compared with a normal gene or a house-
keeping gene normally expressed in all living cells. However, in the present study, the method 
is a quantitative detection method where the target primers competitively bind to the target 
gene in the unknown sample cDNA or the cDNA template with known amount of template 
copy numbers. Since the template with high concentration external standard will bind more 
primer than the unknown sample, the specific bands for the sample will increase in intensity 
in the same way that the band intensities for the template decrease (Figure 7).  
This method was implemented in Göteborg in 1997 and used for several years, but has during 
recent years been replaced by a less labor intensive, more sensitive and reproducible real-time 
PCR (SmartCycler, Cepheid, USA) as previously described (141). 
 
 
The second mesothelial study (Paper III) 
Question 
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The third paper addressed the question whether hyaluronan affects expression of fibrinolytic 
components in cultured human peritoneal mesothelial cells at the protein and mRNA level. 
 
Hyaluronan based agents have been used in clinical settings to reduce the formation of post-
surgical adhesion and the mechanism of action is believed to be a physical separation of 
tissues. However, it is reasonable to assume that there might be a local effect on the 
mesothelial lining, and on fibrinolytic capacity since has biological effects. In this third work, 
the mesothelial cell culture model was further used, as well as assay systems for detecting 
proteins in culture media and intra cellular mRNA. 
 
Mesothelial cell culture 
Human peritoneal mesothelial cells were isolated, cultured and characterized in the same 
manner described earlier (Paper II). For this experimental model, mesothelial cells were 
isolated from five patients undergoing colorectal surgery for non-infectious reasons. Cells 
from the third passage were used for all experiments. 
 
The experimental model 
Hyaluronan has been reported to reduce intra-abdominal adhesions and abscesses in an animal 
adhesion model of peritonitis (142). From this study it was hypothesized that hyaluronan 
could achieve these effects by modulating local fibrinolytic capacity at the peritoneal surface. 
For this reason, an experimental model was designed to study possible local mechanisms. The 
use of TNF-α to simulate an ongoing inflammation and LPS to simulate an established 
infection, has been used in different experimental models (35, 36). Frequently used 
concentrations are 10µg/mL (for LPS) and 500 U/mL (for TNF-α) and these concentrations 
were used for this experiment. 
 
Mesothelial cells in the third passage were cultured until confluent layers were established. 
Following TNF-α (Genzyme, Cambridge, MA, USA) addition to a final concentration of 500 
U/mL in culture media, hyaluronan was immediately added. The concentration of hyaluronan 
(Genzyme, Cambridge, MA, USA) when used in a clinical setting is 0.4%. Several 
concentrations (0.1, 0.2 and 0.4%) of hyaluronan were used to investigate a possible dose-
response. Control cells received medium only. 
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After 24 hours of incubation, the conditioned media were collected from each well and stored 
in several aliquots at -80°C. When all culture media were aspirated, Trizol reagent was added 
in order to prepare the total RNA in the same manner as previously described (Paper II). 
Since t-PA can be stored intracellularly it was of interest to investigate whether cultured cells 
contained t-PA or other fibrinolytic components that could be measured in the cell lysate. In 
preparation to assay for intracellular proteins, the cells were frozen to -80°C and then thawed 
in the incubator at 37°C. This cycle was repeated 3 times to disrupt the cell membranes. After 
the last cycle the cell suspensions were stored in several aliquots at -80°C until assayed. Since 
not both total RNA and intracellular proteins could be assayed on the same cultured cells, 
cells were divided in two equal groups where half of the cells were for total RNA preparation 
and the other half for the intracellular proteins measurements. 
 
Biochemical assays 
The assays used in the present study were similar to the ones presented in the first and second 
study. Plasminogen activators and inhibitors were analysed using commercially available 
ELISA kits. The levels of t-PA and PAI-1 antigen were analysed with kits from Biopool and 
uPA antigen levels were analysed using a kit from Monozyme (Hoersolm, Denmark). Since 
the cell count per cm2 did not differ between wells, the measured values (ng/mL) were 
recorded and not normalised to cell count.  
 
Detecting the mRNA levels 
In order to investigate levels of mRNA for t-PA, uPA and PAI-1, the same methodological 
techniques were used as described in Paper II. In summary, total cellular RNA from treated or 
non-treated human mesothelial cells were used for RT-reaction and standard PCR with 
increasing internal cRNA (104 to 108) copies per reaction. Each PCR product was separated 
on an agarose gel, photographed and scanned. Using NIH-Image software, the band 
intensities were measured and the base-pair corrected ratio between the template and sample 
was plotted against the template copy number in a log-log graph. The concentration in the 
unknown samples is defined where the ratio is equal to 1. Found concentrations are expressed 
as mRNA copies per total µg RNA.  
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The third mesothelial study (Paper IV) 
Question 
The fourth paper addresses the question whether increasing concentrations of hyaluronan 
affect the rate of proliferation of cultured human peritoneal mesothelial cells. 
 
The anti-adhesion effects of hyaluronan have been discussed. The beneficial influences of 
hyaluronan on wound healing and its important regulatory effects in the inflammatory 
response, together with its effect in cell migration and attachment by interactions with cell 
surfaces have been described (99, 102, 103). Hyaluronan may have similar effects in 
peritoneal repair and therefore the action of hyaluronan based adhesion barriers is not solely 
restricted to mechanical properties. To further investigate the role of hyaluronan in peritoneal 
repair, the effect on mesothelial proliferation rate was investigated. 
 
Mesothelial cell culture 
Human peritoneal mesothelial cells were isolated, identified and cultured as described in 
Paper II and III. All experiments were done before the third passage of cells. 
 
Mesothelial cell proliferation 
In order to have an understanding of impact of mesothelial repair, a first step was to 
investigate the proliferation rate of cultured cells. Options to measure proliferation rate 
included counting viable cells after staining with a vital dye, to measure DNA synthesis, or 
counting cells by automated counters which rely on dyes and cellular activity at different time 
points during the experimental process. In this experimental model, a specific colour substrate 
based on the sodium salt of 2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
carboxyanilide inner salt or XTT (Sigma) was used. This XTT-method is based on the 
cleavage of the tetrazolium ring of XTT, by mitochondrial dehydrogenase in viable cells 
resulting in water soluble orange formazan crystals. The orange solution is measured 
spectrophotometrically at a wavelengt of 450 nm (143, 144) indicating an increase or decrease 
in viable cell numbers between different wells. 
 
This method was established and utilized in a 96-well cell culture system to enhance optical 
density readings at 450 nm in a multi well plate reader utilizing computer software (V-max 
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and SoftMax Pro, Molecular Devices, USA). Cell culture medium without phenol red was 
used to reduce the color background in the proliferation assays. When a proliferation assay 
was performed, the remaining medium was removed and replaced with complete culture 
medium E199, without phenol red, containing 200 µg/mL XTT for an additional 4 hours in a 
culture incubator. The optical density at 450 nm was measured with a reference wavelength of 
690 nm subtracted according to the manufacturer, and expressed as a per cent of the untreated 
control. 
 
The experimental model (1) – Absence of inflammatory mediators 
Rapid mesothelization is favourable in peritoneal healing since it restore tissue integrity 
earlier. A peritoneal defect is considered healed when mesothelization is completed. The 
origin of mesothelial cells that contribute to the mesothelial repair is not fully understood. It 
has been shown that mesothelial cells migrate from the edges of the denuded area, 
differentiate from underlying cells or originating from a population of “free-floating” cells 
that can form islands of mesothelium in the defect (Figure 3) (16, 38). In the experimental 
models described below, remesothelization was simulated both with non-attached cells and 
attached cells to reflect different mechanisms of remesothelialization. 
For this reason, the first experiment (Figure 8, 1a) investigated the effect of hyaluronan on 
non-attached cells. Mesothelial cells were detached from the culture flasks using Trypsin-
EDTA solution, centrifuged, resuspended in fresh culture medium and then counted in a 
Bürker chamber. Cells were transferred at a density of 30 000 cells/well into a 96-well multi-
well plate. Hyaluronan was added to the medium in concentration of 0.05, 0.1, 0.2 and 0.4% 
and incubated. Control cells received medium only. The colorimetric proliferation assay with 
XTT was performed after 4 and 24 hours of incubation. 
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The second experiment (Figure 8, 1b), investigated the effect of hyaluronan on attached cells. 
Mesothelial cells were detached in the same manner as described, but the cells were allowed 
to attach to the surface and to each other. During this time, the cells reached an approximate 
confluence of 80%. The cells were then exposed to the same concentrations of hyaluronan as 
described above and colorimetric proliferation assay with XTT was performed after 4 and 24 
hours of incubation. 
 
The experimental model (2) – Presence of inflammatory mediators 
In conjunction with abdominal surgery or an intraabdominal infection, mesothelial cells are 
likely to be exposed to inflammatory mediators. In order to simulate this clinical situation, 
two additional experimental models were prepared. In the first experimental setting (2a), 
intraoperative contamination of gastrointestinal contents was simulated. The second 
experiment (2b), simulated an established peritonitis, where the mesothelium has been 
exposed to inflammatory mediators for a longer period of time. 
 
In the second experiment (Figure 9, 2a), attached mesothelial cells with a confluence of 
approximately 80 % were treated with either of LPS 10 µg/mL, TNF-α 500 U/mL or a 
combination of both. Immediately after this treatment, hyaluronan was added to half of the 
wells at a final concentration of 0.2 % without removing the LPS or TNF-α. Medium without 
hyaluronan and LPS/TNF-α served as untreated controls. Separate cell cultures were 
incubated 4 and 24 hours, followed by determination of the proliferation rate. 
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In the last part of experiment (Figure 9, 2b), attached mesothelial cells with a confluence of 
80 % were pre-incubated with the LPS and TNF-α combination for 24 hours, followed by 
addition of hyaluronan 0.2 % to half of the wells, without removing the media containing the 
inflammatory mediators. Similar to 2a, the control cells received medium only and separate 
cell cultures were incubated for 4 or 24 hours. Colorimetric proliferation assay with XTT was 
performed after 4 and 24 hours of incubation. 
 
 
TGF-β  isoforms in vivo and effects on cell proliferation in vitro (Paper V) 
Question 
The fifth and final paper, investigates the presence and activation profile of all TGF-β 
isoforms, compared with that of plasma during surgery. The effect of different TGF-β 
isoforms and their concentrations on mesothelial proliferation rate was also studied. 
 
In a wound healing rat model, the most prominent isoform was TGF-β1 followed by -β2 and -
β3 (145). The presence of TGF-β1 and -β3 has also been demonstrated to be present in 
peritoneal- and adhesion-tissue in humans (146). However, little is known about the presence 
of TGF-βs or the activation profile in peritoneal fluid during surgery. Therefore, the first step 
was to investigate different TGF-β isoforms and activation profiles in vivo.  
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It would also be of interest to determine the effect on proliferation by TGF-β isoforms. A 
decrease in proliferation rate in both epithelial cells and transformed mesothelial cells of 
TGF-β1 have been reported, but the effect of the isoforms TGF-β2 and -β3 of human 
mesothelial cells has not been described. The second step was therefore, to investigate the 
effect of different TGF-β isoforms on mesothelial proliferation rate in vitro. 
 
Human subjects 
The presence and activation profile of TGF-β1, -β2 and -β3 in the peritoneal fluid was 
investigated in this study. Twenty-three patients undergoing elective open surgery for 
colorectal cancer were included. None of the patients had any infection, or signs of 
disseminated disease at the time of surgery. The patients were equally distributed with regard 
to gender (Male/Female: 11/12) and age at surgery (median age Male/Female; 70/71 years). 
Most of the surgical procedures were performed by the same surgeons.  
 
Samples from peritoneal serosal fluid and plasma 
Peritoneal serosal fluid was obtained by enclosing the small bowel in a sterile plastic bag 
within the peritoneal cavity during surgery (53). This technique protects the small bowel from 
damage during surgery and prevents desiccation. Accumulated serosal fluid from the bag was 
collected at the end of surgery (53). None of the collected samples demonstrated blood 
macroscopically. The mean volume of fluid from the bag was 20 mL, with a range of 5-67 
mL. Time from skin incision to collection of fluid ranged from 35 to 264 minutes, with a 
mean of 146 minutes. 
The expression in peritoneal fluid was compared to corresponding venous blood sampled 
during the surgery. Samples were collected in three different tubes; Sodium citrate, Diatube 
(CTAD) (BD, USA) and Stabilyte™ (Biopool) to optimise the different biochemical assays 
that was later to be performed. Both blood and serosal fluid samples were kept on ice (0°C) 
until centrifugation for 10 minutes at 10 000g at +4°C. All supernatants were stored in pre-
labelled aliquots at -80°C until further analysed.  
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Biochemical assays 
In order to compare levels of fibrinolytic components and TGF-β isoforms from peritoneal 
fluid and plasma, some mechanism had to be devised to correct for potential dilution. The 
final choice was total protein content in the fluid. This was performed using the DC Protein 
Assay (BioRad, Hercules, CA, USA). No difference was observed in mean protein content 
between the peritoneal serosal fluid 42.3±10.7 mg/mL and plasma 43.4±6.9 mg/mL 
(Mean±SD), respectively. As this method of normalization allows for comparison across 
different bodily compartments all subsequent enzyme concentrations or activities were 
normalised to the total protein content of each sample. 
 
Assays used in the present study were similar those previously described for earlier studies. 
The levels of t-PA, uPA and PAI-1 antigen were analysed using kits from Biopool. The active 
fraction of t-PA was measured using Chromolize tPA (Biopool). This method was also 
modified for general plasmin detection (Figure 10). 
 
 
 
Likewise, commercially available methods were used for detecting TGF-β isoforms. The 
method from Promega was used (Paper I) for detecting TGF-β1. TGF-β2 was also analysed 
using a method from Promega. According to the manufacturer, the lower detection limit for 
TGF-β2 was 32 pg/mL. The intra-assay variations were 7.4% at 767 pg/mL and 9.2% at 229 
pg/mL. The inter-assay variations were 6.1% at 756 pg/mL and 27% at 94 pg/mL, indicating 
the method was less sensitive at low concentrations, close to the lower detection limit. For 
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TGF-β3 a commercially available ELISA from R&D Systems (Abingdon, UK) was used. No 
lower detection limit or intra/inter assay variation was specified by the manufacturer. 
Therefore, the lower detection limit was defined as the lowest level that could be 
distinguished from the blank sample, typically 3 standard deviations above the mean optical 
density of the blank. The intra- and inter-assay variations were determined by analysing one 
sample with low and one sample with high concentrations, in replicates (n=4-6) within the 
same plate (intra-assay CV%), and with repeated measures between several plates (inter assay 
CV%). The lower detection limit thus calculated for the TGF-β3 was 25 pg/mL and the intra- 
and inter-assay variations (CV) were 2-4% and 5-12%, respectively, depending on high or 
low concentrations. Higher concentrations gave a lower variability in CV%, in contrast to the 
lower concentrations that frequently varied between 10-12%. Measurements of active and 
total amounts of TGF-β isoforms were similar among the different assays. The active 
fractions could be measured directly in the ELISA plate using the kits provided. However to 
measure the total amount of TGF-β isoforms each sample needed to be acidified to pH 3.0 
using 1 mol/L HCl, followed by a 15-min incubation at 22°C, resulting in activation of all 
TGF-β. To neutralise samples, 1 mol/L NaOH was supplemented before additional dilution 
and application to a second ELISA plate, according to the manufacturer’s instructions. All 
results were normalized to total protein content using the DC protein assay. 
When analysing venous blood for t-PA, Stabilyte™ plasma was used for t-PA activity, and 
for PAI-1 antigen the Diatube (CTAD) plasma was used. For the t-PA antigen, uPA antigen 
and TGF-β assays citrated plasma was used.  
 
Mesothelial cell proliferation 
With an experimental model to study human mesothelial cell proliferation in place (Paper IV), 
the effect of several concentrations of different TGF-β isoforms on mesothelial cell 
proliferation was studied. Concentrations of TGF-β isoforms found during surgery were used 
for this experiment. In the previously described experimental model, both attached and non-
attached cells were used, simulating different stages in mesothelial repair. In this model, only 
attached mesothelial cells were used to simulate the reaction from intact mesothelial layer in 
presence of different TGF-β isoforms. The XTT based technique to measure mesothelial cell 
proliferation was previously described in detail (Paper IV). Cell culture medium without 
phenol red was used to reduce the colour background. Using a plate reader and computer 
based software optical density was determined and calculated as percent of untreated control. 
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The experimental model; Effects of TGF-β isoforms on mesothelial proliferation 
All three TGF-β isoforms used in the mesothelial proliferation model and all isoforms were 
purchased from R&D Systems, and were suspended in sterile HCl (4 mmol/L) and BSA 
(0.1%) (Sigma) to activate the TGF-β isoforms. Additional dilutions (from 1x10-4 to 1x104 
pg/mL) of activated (acidified) TGF-β1-3 were done in culture medium without phenol red and 
with 1% FCS only. The highest concentration was chosen according to what has previously 
been used (Paper II) and lowest concentrations were similar to that found during surgery. 
 
As previously described in Paper II-IV, primary isolated human peritoneal mesothelial cells 
were cultured until the second or third passage. From the second passage, mesothelial cells 
were subcultured to 96-well cell culture plates with a cell density of 2x104 cells/well and were 
maintained for 3-4 days until cultures were 70-80% confluent. Mesothelial cells were 
preincubated for 24 hours with medium containing 1% FCS only and then stimulated with 
increasing concentrations (from 1x10-4 to 1x104 pg/mL) of acidified and activated TGF-β1, -β2 
and -β3 for 16 hours in culture medium with 1% FCS only and without phenol red. Cells 
cultured with medium only, served as untreated controls. Mesothelial cell proliferation (XTT-
assay) was measured by adding substrate to a concentration of 200 µg/mL in medium without 
phenol red. The formed Formazan salt product was measured by light absorbance at 450 nm 
in a 96-well plate reader. A reference wavelength of 690 nm was used to subtract background. 
Proliferation was calculated for all TGF-β isoforms at each concentration as percent of 
untreated cells on the same cell culture plate. For each TGF-β isoform experimental models 
were run in duplicates, and expressed as Mean±SD of six replicates at each concentration, in 
each experiment. Data is presented in bar graphs, where proliferation is expressed as percent 
of untreated cells. A positive bar represents an increase compared to control and a negative 
bar for a decrease in cell proliferation.  
 
Correlation between TGF-β and fibrinolytic components 
It has been proposed that plasminogen activators, t-PA and uPA alone or in combination, can 
activate TGF-β through the plasmin system (147, 148). However, it is not known if this is 
relevant in the abdominal cavity during surgery. Levels of t-PA activity in peritoneal serosal 
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fluid were therefore correlated with corresponding active TGF-β1-3 isoforms to determine 
possible associations between these components.  
 
 
Statistics 
Statistical methods and calculations used in the different papers are presented in this section. 
The outcome and interpretation of the statistical evaluations will be discussed in the Results 
and Discussion section. Statistical significance was defined as p≤0.05 and all tests were 2-
tailed. Statistical calculations were performed using the StatView package (Abacus Concepts, 
Berkeley, CA, USA). 
 
Paper I 
In the first study, the majority of figures are presented as Box-Whisker plots, where the 
median value and inter quartile range are given, together with the 10th and 90th percentile. 
Hence, 80% of all data points are presented in the graphs. Some of the variables measured 
were normally distributed which was confirmed by Kolmogorov-Smirnov test for normality. 
However, since not all variables were normally distributed and the total number of patients 
limited, non-parametric statistics (Mann-Whitney U test) was used to analyse differences 
between groups. Linear regression was used to investigate correlations. Linear or 4-parameter 
regression was used to calculate assay concentrations for the biochemical parameters. 
 
Paper II 
In the second study, results are reported as means±standard error of the mean (Mean±SEM) in 
6 replicates, presented per 106 cells. For the protein detection assay, a statistical analysis was 
made in two steps. A non-parametric Kruskal-Wallis test was first use to determine whether 
there was an overall difference between the separate groups. If results achieved statistical 
significance, the non-parametric Mann-Whitney U test was used to compare different 
concentrations to untreated control. The least square linear regression method was used to 
calculate the fit of the serial dilutions in the Q-RT-PCR reactions. In order to investigate 
whether t-PA or PAI-1 influenced the concentration of t-PA/PAI-1 complex a multiple linear 
regression was performed. Linear or 4-parameter regression was used to calculate assay 
concentrations for all biochemical parameters. 
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Paper III 
Non-parametric statistics were used (Kruskal Wallis and Mann-Whitney U test) similar to the 
previously described. Results are reported as Box-Whisker plots. Linear or 4-parameter 
regression was used to calculate assay concentrations for all biochemical parameters. 
 
Paper IV 
The proliferation rate was measured as optical and expressed as per cent of untreated cells 
(100%). Results are presented as mean and standard error of the mean (Mean±SEM) of 8 
replicates. The non-parametric Kruskal-Wallis and Mann-Whitney U test was used for 
determination of differences.  
 
Paper V 
Comparison of age and gender and of the total protein content between the two compartments 
(peritoneal fluid/plasma) was done with non-parametric (Mann-Whitney U) statistics. The 
analysis between the serosal fluid and plasma within the same patient were done with the 
paired non-parametric Wilcoxon signed rank test. Linear or 4-parameter regression was used 
to calculate assay concentrations for all biochemical parameters. Correlations were done using 
the non-parametric Spearman Rank Correlation test. 
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RESULTS AND DISCUSSION 
The initial human study (Paper I) 
The study 
In the first study, the role of TGF-β1 in peritoneal tissue of patients with adhesion formation 
and its relationship in tissue with decreased fibrinolytic capacity was investigated. Levels of 
active and total TGF-β1 were measured in the extracted tissue, and correlated with assayed 
fibrinolytical factors. Finally, severity of adhesions was scored. 
 
Results 
All 22 patients undergoing surgery had pre-existing adhesions. Thirty-one of 32 biopsies had 
detectable TGF-β1 levels. On average, the adhesion contained higher levels of both active and 
total fraction of TGF-β1 compared to the levels in the peritoneum itself (Figure 11). There 
were also higher levels of the active fraction of TGF-β1 in tissue sampled from patients with 
severe adhesions compared to those with less severe adhesions. The levels of total TGF-β1 
was similar in the groups, indicating that a greater fraction of TGF-β1 was in its active form in 
patients with more dense and extensive adhesions (Figure 11). 
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In order to investigate a possible association with the plasmin system, measured values of 
TGF-β1 were correlated with plasminogen activators and the inhibitor PAI-1 (Figure 12). 
There was no correlation between uPA and t-PA with the active or total fraction of TGF-β1 in 
adhesion tissue. Similar results were found in peritoneal tissue. However, there was a 
correlation in peritoneal tissue between PAI-1 and the active fraction of TGF-β1 and to some 
extent between PAI-1 and the total fraction of TGF-β1 in adhesion tissue. All further results 
from the fibrinolytic measurements have been previously described (120). 
 
 
 
When patients were scored for severity of adhesions eight of the included patients were 
categorised as having less severe adhesions and 14 patients were assigned to the severe 
adhesion formation category. Several of these had experienced adhesive small bowel 
obstruction. 
 
To our knowledge, this was the first study that describes the findings of transforming growth 
factor in human adhesion tissue. Although the sample size was small (n=22), it showed that 
TGF-β1 was present and that increased levels of TGF-β1 seemed to be associated with 
increased PAI-1 in the tissue. These findings supports a role of TGF-β in adhesion formation 
and extend findings in experimental models (149). 
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Additional methodological considerations 
Early on the protein content was normalised to the wet weight of peritoneal tissue. However, 
this method does not take into account differences in cellularity. Later, a method for 
measuring the total protein content was developed for both tissue extraction (125-127) and in 
vitro systems (150). Both methods correlated well with each other (120). Normalizing to the 
total protein content was later preferred since it was useful in different types of tissue, and 
enable comparisons between compartments (Paper V). 
 
It is important to be aware that homogenised samples represents an average tissue 
concentration with contributions from multiple sources including, mesothelial cells, 
fibroblasts, healthy and diseased cells, normal and reactive cells, extracellular matrix, 
inflammatory cells, blood vessels and blood. In some cases it is acceptable to have the 
combined expression of a tissue such as in this case when a tissue surface could present a 
more or less adhesiogenic surface. In other cases, it might be important to generate 
information from a subgroup of cells. The laser capture microdissection (151) could be used, 
or experimental models of isolated cells (35, 131, 141) as reviewed by Ericsson et al (129). 
 
A linear regression was used to determine the correlation between active and total TGF-β1 and 
the PAI-1 level. However, a parametric linear method is always very sensitive to outliers, 
which is the case for this regression analysis. Two high concentrations of the TGF-β1/PAI-1 
could to some extent, affect the outcome of the correlation and significance testing. It is 
debatable whether a non-parametric analysis would have affected the outcome of the 
correlation, since conclusions drawn from 10 individuals are limited. However, when the 
same regression analysis was done with non-parametric statistics (Spearman Rank 
Correlation) some time after the publication of the paper, the correlation remain significant 
between the active fraction of TGF-β1 and PAI-1 in peritoneal tissue (ρs=0.755, p<0.05), 
while the correlation in the adhesion tissue no longer was statistically significant (ρs=0.409, 
p=0.219). This could be either due to the outliers, or to the small sample size (beta error). 
However, robust correlation between the active fraction of TGF-β1 and PAI-1 in the 
peritoneal tissue supports the hypothesis that expression of TGF-β1 is associated with PAI-1 
expression which is likely to have an impact on ECM deposition, and on factors in the 
plasmin system (38, 152). 
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The first mesothelial study (Paper II) 
The study 
In the second study the role of increasing concentration of TGF-β1 on fibrinolytic expression 
in human cultured peritoneal mesothelial cells was investigated. Levels of plasminogen 
activators and plasminogen activator inhibitor were measured in conditioned culture media, 
thus reflecting the secretion of proteins from mesothelial cells. This was combined with an 
investigation of mRNA expression in order to study transcriptional regulation for these 
proteins. 
 
Results 
Cultured mesothelial cells secreted t-PA, uPA, PAI-1 and PAI-2 into the conditioned culture 
media. The conditioned medium also contained t-PA/PAI-1 complex indicating that a 
complex formation between t-PA and PAI-1 had occurred.  
Both Rougier et al (95) and Tietze et al (93) have used TGF-β1 in different cell culture 
models. Rougier (95) used from 0.1 to 10 ng/mL of TGF-β1  in an immortalized mesothelial 
cell line. Tietze (93) used, TGF-β1 in concentrations ranging from 0.0001 to 10 ng/mL, when 
investigating it’s  effect on omentally derived mesothelial cells. Therefore, this study used a 
concentration between 0.1 and 10 ng/mL TGF-β1. Cultured mesothelial cells decreased the t-
PA release with increasing concentrations of TGF-β1 in the culture media (p<0.01), in a dose 
dependent manner (Figure 13). At a concentration of 0.1 ng/mL of TGF-β1 t-PA secretion was 
significantly decreased to 52% of untreated control cells (p<0.01), and continued down to 
63% of control at 10 ng/mL. 
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The opposite was observed for PAI-1, with an overall dose dependent significant increase in 
secretion of PAI-1 (p<0.001) with increasing concentrations of TGF-β1 (Figure 13). At the 
lowest TGF-β1 concentration (0.1 ng/mL) PAI-1 release increased 59% compared to untreated 
control (p<0.01), and at 1 ng/mL, the increase was more than 100% compared to the control 
(p<0.01). No further increase was detected at the 10 ng/mL concentration of TGF-β1. 
 
Interestingly, the concentrations of t-PA/PAI-1 complex followed the secretion of t-PA 
antigen levels with a significant overall decrease in formed t-PA/PAI-1 complex (p<0.001) 
(Figure 14). A significant 50% reduction compared to untreated control was seen at the lowest 
concentration of 0.1 ng/mL TGF-β1 (p<0.01). A multiple linear regression was performed to 
find out whether the decrease in t-PA/PAI-1 complex was influenced by either t-PA or PAI-1, 
and it was found that the decrease was influenced by the levels of t-PA antigen (r2=0.84, 
p<0.001), while PAI-1 antigen levels did not correlate at all. This is likely a reflection of rapid 
inhibition of t-PA secreted into the culture media by the higher concentrations of PAI-1. 
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These findings contrast with other findings where the t-PA/PAI complex increased in 
conditioned media with increasing concentrations of TGF-β1 (95). The reason for this is not 
known. One explanation could be differences in cell phenotypes since other work was done 
on omentally derived mesothelial cells and the present study used mesothelial cells from 
peritoneal fluid. Omentally derived cells did not secrete any uPA or PAI-2 (95), which were 
secreted by mesothelial cells in the present study indicating a phenotype difference. Both uPA 
and PAI-2 were secreted into the culture media during unstimulated conditions and were 
unaffected by increasing concentrations of TGF-β1. 
 
It was not possible to measure any active t-PA in culture media using the t-PA activity 
method. The reason for not detecting active t-PA could have several explanations. It was 
possible to measure the inactive t-PA/PAI-1 complex in a dose dependent manner in the 
culture medium. The presence of the complex indicates a rapid complex formation between t-
PA and PAI-1, and quenching of t-PA activity is likely to have occurred. The PAI-1 antigen 
level in the culture media was much higher than the level of t-PA antigen, indicating an 
overabundance of PAI-1, which would support this notion. Interestingly, if these findings 
accurately reflect the human condition, the presence of high amounts of intraperitoneal TGF-
β1 has the potential to quench fibrinolytic activity. 
 
In the present study, human peritoneal mesothelial cells also expressed t-PA, uPA, PAI-1, 
PAI-2 and uPA receptor mRNA during unstimulating conditions. Increasing concentrations of 
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TGF-β1 decreased mRNA for t-PA in a dose-dependent manner, while it upregulated mRNA 
expression for uPA and uPA receptor. There was low or no effect of TGF-β1 on PAI-1 
(Figure 15) and PAI-2 mRNA expression at the time point measured. However, since there 
was an accumulation of PAI-1 over time, transcription is likely to have occured at some other 
time point. 
The downregulating effect of TGF-β1 on t-PA production is seen in less expression of mRNA 
copies (Figure 15), as well as a decreased secretion of t-PA in culture media. This observation 
confirms earlier findings (93, 95) and extends the observation that the local effect of TGF-β1 
on mesothelial cells is not only dose dependent, but also has profound effects even at low 
doses. Thus, TGF-β1 has the potential to play an important role by significantly depressing 
local fibrin clearing capacity intraperitoneally. 
 
 
The effect of TGF-β1 on PAI-1 is complex. Although the present study demonstrated a dose-
dependent increase in protein secretion into the culture media, a similar pattern was not seen 
in the expression of mRNA for PAI-1. This is in part, in conflict with other findings where an 
increase in mRNA expression was observed in human bronchial epithelial cells (94) and 
immortalized mesothelial cells (93, 95). The reason for this is unclear. However, the cell 
phenotype used in these studies is not the same as the cells used in the present study. It may 
be that different cell phenotypes react differently. Furthermore, the time point for total RNA 
preparation varied among the studies. In the present study (Paper II), RNA preparation took 
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place after sampling from the culture media, which was 24 hours after stimulation. In other 
studies time points between 4 and 12 hours (93, 95) were used. Thus, a rapid increase in PAI-
1 mRNA after TGF-β1 stimulation, might have been unnoticed with the present study design. 
 
This experimental model suggests that the effect of TGF-β1 is not limited to promotion of 
tissue fibrosis, but also affects peritoneal fibrin clearing capacity by differentially regulate 
local fibrinolysis with decreasing t-PA and increasing the inhibitor PAI-1 secretion. These 
observations further support a role for TGF-β1 in adhesion formation. 
 
 
The second mesothelial study (Paper III) 
The study 
In the third study, using an inflammatory experimental model, the role of increasing 
concentrations of hyaluronan on human cultured mesothelial cells was investigated. Secreted 
levels of plasminogen activators and plasminogen activator inhibitor were measured in 
conditioned culture media. Intracellular mRNA expression was investigated for the same 
reasons previously described in Paper II. Since t-PA can be stored intracellularly, proteins 
were also measured in mesothelial cells lysates.  
 
Results 
Cultured mesothelial cells secreted t-PA, uPA and PAI-1 in both the conditioned media and 
cell lysate. TNF-α and different concentrations of hyaluronan did not significantly change t-
PA concentration in the culture media. However, when levels of t-PA antigen were measured 
in cell lysates, the concentrations were significantly increased in a dose dependent manner 
with increasing concentrations of hyaluronan. The amount of mRNA copies for t-PA, 
measured at 24 hrs after stimulation, did not change in the presence of hyaluronan. 
 
The intracellular amount of t-PA increased with increasing concentrations of hyaluronan 
(Figure 16), suggesting mesothelial intracellular pooling, which has previously been described 
as occurring in endothelial cells (153). One mechanism could be that hyaluronan affects t-PA 
release at a post-translational level. However, since no effect was seen on the mRNA 
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expression for t-PA, there was no indication that t-PA was transcriptionally regulated by 
hyaluronan. 
 
 
 
When uPA antigen levels were measured in culture media, their concentrations decreased 
significantly in a dose dependent way, with increasing concentrations of hyaluronan.  
However, uPA levels did not change when measured in the cell lysate. When the mRNA for 
uPA was measured with the Q-RT-PCR method, an increase in messenger RNA copies from 
2x102 to 4x105 was observed after treatment with hyaluronan, which is a 1000-fold increase 
in the hyaluronan treated cells compared with the untreated control. 
 
Hyaluronan decreased PAI-1 antigen levels in conditioned culture media compare to 
untreated controls, with the most profound effect at a hyaluronan concentration of 0.4% 
(Figure 16). There was no difference in PAI-1 levels in cell lysate compared to expression in 
medium. At the mRNA level, hyaluronan caused a 500-fold decrease in PAI-1 mRNA 
expression, from 6x104 to 1x102 copies per microgram of total RNA.  
This is in part, in contrast with the findings of Tarhan et al (111) where the effects of a HA-
CMC gel (Seprafilm) on the fibrinolytic system was investigated in a rat model. In that study, 
uPA was significantly decreased in peritoneal tissue in the HA-CMC group compared to 
control, and no difference were seen between the two groups for t-PA, PAI-1 or PAI-2 (111). 
The reason for this is unclear, however the experiments were performed using rat peritoneal 
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tissue, whereas human mesothelial cells were used in the present paper (Paper III) and the 
experimental conditions were different. 
 
Despite the seemingly contradictory effect on the plasminogen activators it is likely that the 
net effect might be an increase of fibrinolytic capacity, since intracellularly pooled t-PA is 
ready to be released when cells are appropriately stimulated. Moreover, the decrease in PAI-1 
concentrations in the culture medium would also favour an increased fibrin degradation 
capacity. This could potentially translate into a beneficial effect of hyaluronan in the 
peritoneal environment, and lends support to a biological effect. 
 
 
The third mesothelial study (Paper IV) 
The study 
In the fourth study, the role of increasing concentrations of hyaluronan on the proliferation 
rate of attached and non-attached human peritoneal mesothelial cells, with or without 
inflammatory mediators, was investigated.  
 
Results - Proliferation in the absence of inflammatory mediators 
When proliferation was measured in non-attached cells, increasing concentrations of 
hyaluronan increased the proliferation rate in a dose dependent manner at both 4 and 24 hours 
(Figure 17). The most profound effect was found at the 0.4% concentration of hyaluronan (4 
hours p<0.01, 24 hours p<0.005), (experimental model 1a in Paper IV). 
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Similar to non-attached cells, the presence of hyaluronan increased the proliferation rate when 
measured at 4 and 24 hours. At 4 hours the difference was statistically significant using 0.2% 
hyaluronan (p<0.01) and at higher concentrations. At 24 hours, the difference was significant 
already at 0.05% (p<0.01) and gradually increased in a dose dependent manner (experimental 
model 1b in Paper IV).  
 
When the proliferation rate was compared between the non-attached and attached cells, the 
rate was significantly increased in the attached cells. This suggests that cells needs to be close 
to each other or to a surface for this effect to be observed. Furthermore, when the proliferation 
rate was compared between the two time points, the proliferation rate was reduced to 50% in 
control cells at 24 hours compared to the rate at 4 hours. The reason for this is not known, but 
it is likely the cells reached a confluent state within the experimental time period, since the 
cells were already approximately 80% confluent when the experiment started and further 
proliferation was inhibited. Similar contact inhibition was not seen when the transformed 
mesothelial cell line Met-5A was used. This suggests that primary isolated human peritoneal 
cells are capable of regulating their own proliferation rate and reduce or end it when 
mesothelization is complete. 
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Proliferation in the presence of inflammatory mediators 
In order to investigate different inflammatory conditions in the peritoneal cavity, shorter 
(inflammation model) and longer (peritonitis model) exposure time of inflammatory 
mediators was examined. Based on previous observations all experimental models were 
performed on attached mesothelial cells. 
 
 
In the inflammation model, exposure of LPS, TNF-α or their combination for four hours did 
not affect mesothelial proliferation (Figure 18). However, exposure of TNF-α alone or in 
combination with LPS for 24 hours reduced the proliferation rate to 75-80% compared to the 
untreated control (p<0.005). 
When hyaluronan was added immediately after exposure to LPS, TNF-α or the combination, 
the proliferation rate was increased at both the 4 (p<0.05) and 24 (p<0.001) hour time points. 
 
In the peritonitis model, 24 hours preincubation with inflammatory mediators resulted in a 
significant decrease in mesothelial cell proliferation (Figure 19) with the most profound effect 
by TNF-α and TNF-α in combination with LPS. However, exposure of cells to hyaluronan 
for 4 hours in addition to 24 hours preincubation had a protective effect and increased the 
proliferation rate of mesothelial cells preincubated with LPS, TNF-α or a combination of both 
(p<0.001) compared to untreated controls. 
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The mesothelial cell cultures did not survive an exposure to the inflammatory mediators for 
48 hours (24 hours preincubation with inflammatory mediators and additional 24 hours with 
or without hyaluronan). 
With the above-mentioned experiments it could be demonstrated that hyaluronan increased 
the mesothelial cell proliferation in vitro even in the presence of inflammatory mediators. It 
could also be demonstrated that prolonged exposure to inflammatory mediators had a 
detrimental effect on mesothelial cell proliferation rate. 
 
There are several ways by which hyaluronan can affect mesothelial cell proliferation. It might 
have effects on extra cellular matrix synthesis or structure (104) as well as modulation of 
growth factors, stimulation of surface receptor expression, or it could affect cell proliferation 
directly through a receptor  (154). The CD44 receptor is a surface receptor that is involved in 
hyaluronan signalling pathway (155, 156) and a has possible role in cell-cell signalling and 
signal transduction (155). The cultured mesothelial cells in the present study expressed the 
CD44 surface antigen when incubated with a FITC labelled mouse anti-human CD44 
antibody (Sigma, St.Louis, MO, USA) and exposed to UV-light in the inverted cell 
microscope. It is possible that the effect in mesothelial cell proliferation is mediated through 
the CD44 receptor, but this remains to be shown. 
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The main principles of action for hyaluronan based adhesion barriers is considered to be a 
mechanical separator of damaged peritoneal surfaces. As several of the hyaluronan-based 
agents on the market are modified in some way it is possible that their effect may differ. 
However, these findings suggest that a hyaluronan based adhesion barrier also could have 
biological effects in the peritoneal cavity. 
 
 
TGF-β  isoforms in vivo and effects on cell proliferation in vitro (Paper V) 
The study 
In the fifth and last study the presence and activation profile of TGF-β was further 
investigated and extended to include all three isoforms of TGF-β1-3. Since TGF-β1 was found 
in peritoneal tissue during surgery (Paper I) and had effects on mesothelial fibrin clearing 
capacity (Paper II) it was of interest to further characterise all present isoforms. This was done 
together with measurements of fibrinolytical factors in both peritoneal serosal fluid and 
plasma during surgery. Additionally, in an experimental model the effect of TGF-β1-3 on 
human mesothelial cell proliferation was studied. 
 
Results – Presence and activation profiles of TGF-β1, TGF-β2 and TGF-β3 
In the first part of the study peritoneal serosal fluid and plasma levels of TGF-β isoforms were 
investigated. In both serosal fluid and plasma we found detectable levels of total and active 
fractions of the TGF-β1-3 isoforms (Table 2). 
 
The active fraction of TGF-β1 was higher in peritoneal serosal fluid compared with the 
corresponding plasma samples (p<0.01) (Table 2). In contrast, the levels of total TGF-β1 in 
serosal fluid did not differ from the levels in plasma. This indicates that an increased 
activation of TGF-β1 had occurred in the peritoneal environment. 
 
Similar to TGF-β1, the active fraction of TGF-β2 was higher in serosal fluid compared with 
that of plasma (p<0.01), but the concentration of total TGF-β2 was similar in the two 
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compartments (Table 2). Again, this indicates that an activation had occurred in the peritoneal 
compartment. 
 
In contrast, active fraction of TGF-β3 did not differ between the two compartments (Table 2). 
Moreover, the levels of total TGF-β3 were higher in the serosal fluid (p<0.01) compared with 
the concentrations found in plasma. However, the amount of total TGF-β3 was lower 
compared to the other isoforms in both set of samples. It therefore appears as TGF-β3 is 
differentially affected in comparison to the other isoforms. 
 
 
The pattern with increased active fraction of both TGF-β1 and TGF-β2 is comparable to what 
has been described in tear fluid in humans (157). The authors reported rather low, but 
detectable levels of the active fractions of TGF-β1 and TGF-β2, with substantially higher 
concentration of total TGF-β1 and TGF-β2. 
 
Presence of fibrinolytic factors 
Both serosal fluid and plasma showed detectable levels of t-PA, uPA and PAI-1 (Table 3). t-
PA was measured both as an active fraction (t-PA activity) and as a total antigen (t-PA 
antigen). The levels of t-PA and uPA were higher in the peritoneal serosal fluid samples 
compared with the levels in plasma. This is similar with the findings described earlier (53) but 
with the difference that also uPA was increased in the peritoneal serosal fluid. In contrast to 
the activators, PAI-1 levels were lower in serosal fluid compared with plasma. 
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A possible cause for the increased levels of plasminogen activators in the peritoneal cavity 
during surgery might be the release of activators from the mesothelial layer. Previously it 
could be demonstrated that endothelial cells could store t-PA intracellularly (153). In the 
present work (Paper III) mesothelial cells seemed to have a similar storage function. It might 
be that a similar mechanism could be involved in vivo enabling a rapid release into the cavity.  
 
Correlations of TGF-β and fibrinolytic components 
It has been proposed, based on experimental models (147, 148, 158) that plasminogen 
activators can activate TGF-β through the plasmin system. To investigate this, a correlation 
(Spearman Rank Correlation) was made between t-PA activity in serosal fluid (Table 3) with 
corresponding active TGF-β1-3 isoforms (Table 2). A positive trend was detected with all 
three isoforms, however none of these reached statistical significance. In addition, no other 
correlation was seen between t-PA antigen or uPA antigen with any of the active TGF-β 
isoforms. Hence, there does not seem to be a direct relationship between TGF-βs and 
plasminogen activators in peritoneal serosal fluid. 
 
However, the positive trend suggested some kind of relationship. Therefore additional 
experiments were done. This preliminary data indicate that plasmin itself may be related to 
the intraperitoneal activation of TGF-β. Plasmin activity can be measured using a plasmin 
sensitive substrate, identical to the one described for the t-PA activity method, but without 
using the t-PA specific capture antibody. The differences in assay techniques between ELISA, 
and these assays are schematic shown in Figure 10.  
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When plasmin concentrations were compared to the active TGF-β isoforms, there was a 
significant correlation between the levels of plasmin and the active fractions of the TGF-β 
isoforms. The active fractions of TGF-β2 were positive correlated ρs=0.74 (p<0.001) as were 
the active fraction of TGF-β3 with ρs=0.60 (p<0.05). A positive correlation was also found 
between plasmin and the active fraction of TGF-β1, however it did not reach statistical 
significance ρs=0.42 (p=0.061). 
 
These preliminary observations should be interpreted with caution. The concentrations in this 
experimental model were calculated against a t-PA standard, and it can be argued that a 
plasmin standard could be more appropriate to use. Furthermore, due to limited remaining 
sample volume only samples from 15 of 23 patients could be used. Nevertheless, these 
findings indicate that the resulting plasmin seems to be of greater importance than t-PA or 
uPA alone. Locally generated plasmin might thus be a mechanism by which activation of 
TGF-β in the abdominal cavity occurs, but further research is needed. 
 
Effect of TGF-β1-3 on proliferation rate of mesothelial cells 
The effect of the TGF-β1-3 isoforms on the proliferation rate of cultured human peritoneal 
mesothelial cells were tested by the XTT-assay as a marker of viable cells (Paper IV) (144). 
In the figure the effect of different concentrations of each TGF-β isoform on the proliferation 
rate of the mesothelial cells is expressed as percent of untreated controls.  
 
An increase in proliferation is indicated by a bar graph above 0%, and a decrease is indicated 
with at bar below 0% (Figure 20). Similar to what has been described earlier (78, 159, 160) 
for TGF-β1 a 50% reduction in cell proliferation was found in the present study when cell 
cultures were exposed to high concentrations (5x103-1x104 pg/mL) of TGF-β1-3 isoforms. 
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Interestingly, there was an increase in mesothelial cell proliferation in the presence of TGF-β1 
at 0.1 to 50 pg/mL compared to untreated control (Figure 20). Moreover, the TGF-β1 effect 
was present at concentrations found in the peritoneal serosal fluid from patients during 
abdominal surgery. TGF-β2 and TGF-β3 isoforms had no consistent influence on the cell 
proliferation rate. 
 
The increase in mesothelial proliferation at low concentrations of TGF-β1 has to our 
knowledge not been shown previously. Other studies have reported different results and have 
used concentrations in different ranges (78, 159, 160), but not as low as in the present study. 
TGF-β has the ability to affect the cell cycle, proliferation and apoptosis, and in most 
epithelial cells TGF-β is an inhibitor of cell proliferation (83). The mechanism leading to 
increased proliferation therefore remains to be understood. 
 
The concentrations used in this study were found in the surgical setting, and the observations 
are therefore likely to be clinically relevant. This suggests a new role for TGF-β1 in a surgical 
context by enabling a rapid remesothelization during peritoneal repair. 
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FURTHER DISCUSSIONS AND FUTURE PERSPECTIVES 
Experimental models of the human peritoneal environment 
 
Experimental models and mesothelial cells 
It could be discussed how representative the mesothelial cell cultures are for a surgical 
situation, in particular since different sources of mesothelial cells seem to give different 
results. Several research groups have been using omentally derived mesothelial cells, others 
are using transformed cell lines and in the present work we have used mesothelial cells 
derived from peritoneal fluid. It is not possible to evaluate what types of cells that best 
represent conditions in vivo. However, it is reasonable to assume that the free-floating 
mesothelial cells used in the present work, in early passages, is likely to be phenotypically 
similar to intact peritoneum. However, cell culturing is an artificial situation and results 
should therefore be interpreted with caution.  
 
Even if the importance of the mesothelial cell has been increasingly appreciated during recent 
years, some mechanisms regarding regulating functions remain unclear. Experimental models 
of the mesothelial surface continue to be attractive tools to study isolated mechanisms of 
different biological functions in a controlled environment. Controlled experimental settings 
enhance the possibilities to study effects over a longer period of time that might be difficult to 
perform in the clinical setting. During surgical procedures, the peritoneal cavity is available 
only during a short period of time and mechanisms before and after are therefore difficult to 
follow. Thus, experimental models are important in the understanding of biological effects in 
a surgical context. 
 
Models have been used to reflect different mechanisms in human situations as the vascular 
wall (62, 131, 132, 134, 153), in bone or cartilage (86, 88), in the eye (85), the lung (66) and 
wound healing (157, 161).  
Moreover, experimental models have been used studying the mesothelial layer in the 
abdominal cavity. Isolation, culturing and characterizing of mesothelial cells have been 
described (35, 36, 137, 138). Models to study different mechanistic effects have been used for 
fibrinolytic components (20, 35, 36, 93, 95, 141, 150), response to inflammatory mediators 
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(35, 36, 93) (Paper III), growth factors (95) (Paper II and V), mechanisms in cell adhesion 
(33) and cell proliferation (159) (Paper IV and V). Experimental models are critical to the 
understanding of human biology, and could be very useful for the future development of 
surgery. Examples of this are models developed to mimic different surgical techniques 
including laparoscopy (141, 150).  
 
During the development of mesothelial cell models it was noted that cells could not be 
cultured in too many passages without regressing into a fibroblastic phenotype. Due to this 
observation, we believed it was important to conduct the experiments as close to the primary 
isolated culture as possible. Since it was discovered that the morphological and immuno 
specific characteristics for a mesothelial cell type gradually disappeared starting in passage 
four, it was decided to perform all experiments before the fourth passage. However, it is 
noteworthy that, for some of the mesothelial cells the characteristics did not disappear, even 
after passage 10, 15 or even more. These findings were remarkable since the cells could be 
subcultivated repeatedly and still retain their mesothelial phenotype. None of these 
extraordinary cells were included in any of the experimental models, since they did not 
behave as expected. This kind of mesothelial cells have been suggested to be stem cells, that 
might be important candidates in transplantation of mesothelial cells in peritoneal damage 
(162, 163) or even general tissue engineering (164). 
 
TGF-β in experimental models 
In the beginning of this work, we sought to investigate if TGF-β1 was present in peritoneal 
tissue during surgery and further investigate local fibrinolytic effects on the mesothelial cell 
layer. Given the fibrotic effect of TGF-β1, together with reduced fibrinolytic capacity, a 
reasonable approach to reduce adhesion formation seemed to be to reduce the expression of 
TGF-β in the peritoneal cavity. However, the final paper suggests that TGF-β has a multitude 
of effects and that this might not be an entirely correct conclusion.  
 
The biological effects of TGF-β include an ability to initiate synthesis in new tissue, 
interaction with interleukins and cytokines in the immune system, effects on cell proliferation, 
and initiation of cell differentiation in a variety of cell systems (76).  
The different biological functions of TGF-β1 have been investigated in a variety of cell 
culture models. Idell et al (66) described a model of the injured lung where cultured 
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fibroblasts decreased their fibrinolytic capacity by increasing the levels of PAI-1 when TGF-
β1 was added and concluded that TGF-β1 favoured extravascular fibrin deposition. Moreover, 
Overall et al (88) described a model with calvarial bone cells together with fibroblast and 
found that not only the secretion of PAI-1 was increased, but also the release of TIMP, 
together resulting in net accumulation of connective tissue. 
When the release of MMPs and TIMPs from the mesothelial lining in the abdominal cavity 
was investigated in cultured mesothelial cells and monocytes Ma et al (160) found that both 
MMPs and TIMPs were differentially regulated by TGF-β1. Furthermore, Saed et al (165) 
investigated fibrosis and adhesion formation in a hypoxia model of the peritoneal cavity by 
culturing mesothelial cells with a minimum of oxygen present. The authors found an increase 
in Collagen III release from the mesothelial cells after TGF-β1 treatment. Interestingly, the 
authors also found an increase in TGF-β1 release in the hypoxia model indicating a 
pronounced effect of TGF-β1 during hypoxic conditions, which is most likely to occur during 
tissue ischemia. Ischemia was early on identified as a strong stimulus for adhesion formation 
(166). 
 
TGF-β1 has a central role in wound healing and scar formation by stimulating fibrosis. This 
has also been investigated further using experimental models in animals. Roberts et al (87) 
found that granulomas were formed together with collagen production from fibroblasts when 
TGF-β1 was injected in newborn mice. During formation of adhesions this is further 
supported in an experimental rat model described by Williams et al (96) where the number 
and severity of adhesions after addition of TGF-β1 were increased during abdominal surgery. 
The role of TGF-β1 in adhesion formation has been further described by Lucas et al (97). The 
authors found that a standardized surgical procedure induced adhesion formation, and by 
adding an antibody directed specifically to TGF-β1 adhesions could be reduced. However, 
when using an antibody specifically directed to TGF-β2, the adhesions remained. This 
indicates that TGF-β1 is more important in this context than TGF-β2. This is in part in contrast 
with the work done by Gorvy et al (149) where an experimental mouse model was developed. 
The authors manipulated all different TGF-β isoforms to see which isoform of TGF-β was the 
most important in adhesion formation. Their results demonstrated that by blocking both TGF-
β1 and TGF-β2, adhesion formation could be reduced. The reason for this discrepancy is not 
known, however, Gorvy et al (149) suggested that the release of the different isoforms is 
taking place at different time points that is not reflected in the previous study (97). 
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When different TGF-β isoforms were investigated in humans, Chegini et al (146) found that 
both adhesion tissue and serosal tissue of various peritoneal organs express TGF-β1 and TGF-
β3 differently during surgery. The authors concluded that TGF-β1 was more critical in altering 
the outcome of adhesion formation and that the involvement of TGF-β3 remained to be further 
investigated. In the present study (Paper V), all TGF-β isoforms were measured and it was 
notable that active fractions of TGF-β1-2 were increased in the peritoneal serosal fluid 
compared to plasma samples. 
 
In cell proliferation, TGF-β1 has ability to affect the cell cycle, growth arrest, proliferation 
and apoptosis. Additionally, TGF-β1 has previously been reported to inhibit cell proliferation 
(83). In an experimental model with omentally derived mesothelial cells, Pierro et al (159) 
demonstrated that addition of TGF-β1 decreased the proliferation rate more than 60% 
compared to untreated control. This could also be confirmed by Matsuo et al (167) when the 
long term effects of CAPD was investigated and the authors found a decrease in mesothelial 
proliferation with increasing concentrations of TGF-β1. Similar patterns have also been 
described by Zhong et al (168). However, Mutsaers et al (169)  reported that TGF-β1 did not 
have any effect on the proliferation rate. 
 
Hence there are conflicting reports regarding effects of TGF-β isoforms on mesothelial cell 
proliferation. A possible explanation might be that the different TGF-β isoforms have 
different biological functions depending on the concentration. The results obtained during this 
work would support such a notion. Various concentrations of TGF-β1 have been used, 
together with different sources of mesothelial cells potentially explaining the divergent 
results. To summarize these thoughts graphically, a schematic overview is presented 
representing the published literature and results from the current thesis (Figure 21). The x-axis 
in the centre demonstrates the concentrations of TGF-β1together with different biological 
functions in relation to concentration. 
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A decrease in mesothelial proliferation rate at certain concentrations was confirmed in the 
present study and the results also indicate that this effect is concentration dependent. For the 
higher concentrations, a 50% reduction in cell proliferation was observed when cell cultures 
were exposed to TGF-β1-3 isoforms. However there was an increase in mesothelial cell 
proliferation at lower concentrations. Importantly, this concentration is similar to the TGF-β1 
concentration found in the peritoneal serosal fluid from patients during abdominal surgery. It 
is therefore likely that, in a surgical context, TGF-β1 would have a stimulatory effect on cell 
proliferation. 
 
The role of uPA in the peritoneal cavity is poorly understood. Since the main plasminogen 
activator in the peritoneal cavity is t-PA, the role of uPA might not be so important in clearing 
fibrin deposits from the cavity. However, a possible role for uPA in the peritoneal cavity 
might be, alone or in combination with t-PA, local activation of small amounts of TGF-β 
through the plasmin system. 
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Hyaluronan in experimental models 
Hyaluronan is present in most tissues and body fluid and has many biological functions (99). 
One of these is enhancement of the healing process with typically a high concentration of 
hyaluronan in the healing wound (100, 101). Moreover, hyaluronan has been described to 
induce mitosis and detachment and movements of cells (104-106) as it provides a hydrated 
matrix that facilitates cell migration (107). 
The use of hyaluronan based agents in the prevention of adhesions has been used in both 
experimental models in animals (108-111) and in clinical use with a documented reduction of 
adhesions (112-117).  
 
Glycosaminoglycans including hyaluronan have been reported to enhance movement and 
locomotion of transformed cells (106). It is also known that hyaluronan is important in 
angiogenesis (154). Different molecular weights have been reported to have different effects. 
Suzuki et al (102) investigated in an experimental inflammation model, the effects on 
macrophage function and reported dose dependent inhibition of phagocytosis with increasing 
concentrations and molecular weight of hyaluronan. The results indicate that hyaluronan with 
the highest molecular weight had the most profound effect. Reijnen et al (142) described an 
experimental model of peritonitis in the rat where adhesion formation was evaluated. The 
authors concluded that both adhesion formation and abscess formation was reduced when 
using a 0.4 % hyaluronan solution. Hence, it seems as hyaluronan can affect tissue or host 
response to an inflammatory stimuli.  
 
In this thesis, a similar observation was made in Paper III where it was observed that 
hyaluronan could modulate the cellular response to inflammatory mediators. The most 
profound effect was seen with increasing levels of t-PA in cell lysates, and decreasing levels 
of PAI-1 in the conditioned culture media. In the present study, high molecular weight 
hyaluronan was used and it might be that hyaluronan with different molecular weight have 
different effects, in analogy with TGF-β isoforms. 
 
In the experimental models (Paper IV), the mesothelial proliferation rate was increased with 
increasing concentrations of hyaluronan. Influence of inflammatory mediators for a longer 
period of time decreased cell proliferation. However, the presence of hyaluronan reduced this 
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effect, indicating that presence of a hyaluronan based adhesion barrier can have beneficial 
biological effects, even in the presence of inflammation. 
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SUMMARY AND CONCLUSIONS 
 
In this thesis, the focus has been on the use of different experimental models to study effects 
of TGF-β isoforms and hyaluronan during conditions that would reflect common conditions 
in a surgical setting. From these experimental models it can be concluded: 
 
- TGF-β1 is present in peritoneal tissue and higher levels are associated with adhesions. 
 
- TGF-β1 can reduce mesothelial cell fibrinolytic capacity in vitro by decreasing the 
production of t-PA and by increasing the secretion of the inhibitor PAI-1. 
 
- Hyaluronan can affect mesothelial cell fibrinolysis in vitro by increasing t-PA and 
decreasing the secretion of the inhibitor PAI-1. 
 
- Hyaluronan can affect mesothelial cell proliferation in both attached and non-attached 
cultured human mesothelial cells. 
 
- All three TGF-β isoforms are present in the human peritoneal cavity during surgery, 
Detected concentrations of TGF-β1 had a stimulatory effect on cultured mesothelial 
cell proliferation rate, whereas the effect of the two other isoforms were more 
ambiguous. In general, a greater proportion of TGF-β isoforms were in an active 
configuration, indicating that an activation occurred in the peritoneal environment. 
 
- Finally, although TGF-β isoforms, in particular TGF-β1, generally promotes fibrosis, 
and in this work has been demonstrated to reduce mesothelial fibrinolytic capacity and 
thereby facilitate the formation of post-surgical adhesions, its effects may not be 
entirely negative. This thesis also indicates that TGF-β1 can increase mesothelial cell 
proliferation rate, which might be beneficial in the post-surgical repair phase. 
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Sammanfattning på svenska 
Experimentella modeller av den humana peritoneala miljön: Effekter av TGF-β  och 
hyaluronan 
Sammanväxningar (adherenser) efter bukkirurgi är ett stort och ännu olöst problem. Balans 
mellan enzymsystem bestående av bland annat plasminogen aktivatorer (t-PA, uPA) och 
plasminogen inhibitorer (PAI) är av betydelse för postoperativ peritoneal 
läkning/adherensbildning. Dessa enzymer frisätts bland annat lokalt av mesotelceller i 
bukhålan, vilka har en viktig roll vid reglering av den fibrinolytiska kapaciteten. 
Transforming growth factor beta (TGF-β) är en cytokin med många funktioner och effekter 
däribland fibrosbildning och har i djurmodeller visat sig påverka bildningen av adherenser. 
Hyaluronsyra (hyaluronan) förekommer naturligt i kroppen samt har även i kliniska studier 
visat sig reducera förekomsten av adherenser. Hur TGF-β påverkar fibrinolysen i bukhålan, 
samt vilka mekanismer som förklarar den adherensreducerande effekten av hyaluronan är 
oklara. Att studera dessa processer på människa har begränsningar och det är därför 
nödvändigt med experimentella modeller. 
 
Syftet med dessa studier var att analysera lokal peritoneal fibrinolys samt i olika 
experimentella modeller studera effekter av TGF-β och hyaluronan på odlade humana 
mesotelceller. 
 
Studie I: I human peritoneum studerades nivåerna av TGF-β1 och fibrinolyskomponenter (t-
PA, uPA och PAI-1) samt deras relation till adherenser efter tidigare kirurgi. Resultatet visade 
att det fanns ett samband mellan ökade nivåer av TGF-β1 och ökad svårighetsgrad av 
adherenser. Dessutom fanns ett samband mellan ökade nivåer av TGF-β1 och minskad 
fibrinolytisk kapacitet, genom ökad PAI-1.  
Studie II: I experimentella modeller odlades humana mesotelceller vilka utsattes för stigande 
koncentrationer av TGF-β1. Frisättningen av fibrinolyskomponenter i odlingsmediet, samt 
mRNA uttryck från cellerna visade dosberoende minskning av t-PA produktion, samtidigt 
som frisättning av PAI-1 ökade med stigande koncentration av TGF-β1. 
Studie III: I en liknande modell (Studie II) studerades effekten av stigande koncentrationer 
hyaluronan på odlade mesotelceller. Resultaten visade en ökad fibrinolytisk kapacitet genom 
ökande aktivatorer (t-PA) och minskande hämmare (PAI-1) hos odlade mesotelceller. 
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Studie IV: För att ytterligare undersöka effekten av hyaluronan studerades cellproliferation 
hos mesotelceller. Resultaten visade att cellproliferationen ökade med stigande koncentration 
hyaluronan samt att denna tycktes motverka en negativ proliferativ effekt av inflammatoriska 
mediatorer.  
Studie V: Med kunskap från de tidigare studierna samt tidigare beskrivna modeller studerades 
TGF-β1, -β2, och -β3 i human peritonealvätska. Vidare studerades cellproliferation med dessa 
isoformer hos odlade mesotelceller. I jämförelse med respektive plasmanivåer visade det sig 
att de aktiva fraktionerna av TGF-β1 och -β2 var förhöjda i peritonealvätska. Celler som 
stimulerades med koncentrationer av TGF-β1 som motsvarar de normalt förekommande i 
bukhålan ökade cellproliferationen jämfört med kontroll, medan högre koncentrationer hade 
en hämmande effekt. 
 
Konklusion: Vi fann att TGF-β1 förekom i peritoneum samt i adherensvävnad. En påvisad 
korrelation med PAI-1 kan utgöra en bidragande faktor vid post-operativ adherensbildning, 
detta kunde senare stödjas med experimentella modeller på odlade celler. Fynden talar för att i 
bukhålan befintliga nivåer av TGF-β1 kan stimulera mesotelcellers proliferation samt bidra till 
att bibehålla den fibrinolytiska kapaciteten i bukhålan, en viktig kunskap för ökad förståelse 
av postoperativ adherensbildning. 
De experimentella studierna av hyaluronan kan till viss del vara en förklaringsmodell som 
stöder kliniska observationer avseende dess adherensförhindrande effekt. Tänkbara 
bakomliggande mekanismer kan vara ökad lokal fibrinolytisk kapacitet tillsammans med ökad 
cellproliferation. 
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